<SEC-DOCUMENT>0001193125-24-273896.txt : 20241210
<SEC-HEADER>0001193125-24-273896.hdr.sgml : 20241210
<ACCEPTANCE-DATETIME>20241210060555
ACCESSION NUMBER:		0001193125-24-273896
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20241209
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241210
DATE AS OF CHANGE:		20241210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39852
		FILM NUMBER:		241537022

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d905678d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sclxw="http://imetrix.edgar-online.com/20241209" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2024-12-09_to_2024-12-09">Scilex Holding Co</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-315">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-12-09_to_2024-12-09">0001820190</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="sclxw-20241209.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-12-09_to_2024-12-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-12-09</xbrli:startDate> <xbrli:endDate>2024-12-09</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-12-09</xbrli:startDate> <xbrli:endDate>2024-12-09</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-12-09</xbrli:startDate> <xbrli:endDate>2024-12-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-342">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-12-09_to_2024-12-09" format="ixt:datemonthdayyearen" id="ixv-343">December 9, 2024</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">SCILEX HOLDING COMPANY</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-12-09_to_2024-12-09" format="ixt-sec:stateprovnameen" id="ixv-344">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-345">001-39852</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-346">92-1062542</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-347">960 San Antonio Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-348">Palo Alto</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-12-09_to_2024-12-09" format="ixt-sec:stateprovnameen" id="ixv-349">California</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-350">94303</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-351">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-352">516-4310</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-12-09_to_2024-12-09" format="ixt-sec:boolballotbox" id="ixv-353">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-12-09_to_2024-12-09" format="ixt-sec:boolballotbox" id="ixv-354">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-12-09_to_2024-12-09" format="ixt-sec:boolballotbox" id="ixv-355">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-12-09_to_2024-12-09" format="ixt-sec:boolballotbox" id="ixv-356">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" id="ixv-357">Common stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" id="ixv-358">SCLX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen" id="ixv-359">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember" id="ixv-360">Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember" id="ixv-361">SCLXW</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember" format="ixt-sec:exchnameen" id="ixv-362">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-12-09_to_2024-12-09" format="ixt-sec:boolballotbox" id="ixv-363">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2024-12-09_to_2024-12-09" format="ixt-sec:boolballotbox" id="ixv-364">&#9746;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tranche A Consent Letter </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;9, 2024, the Company entered into a Consent Letter (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Tranche A Consent Letter</span></span>&#8221;) with Oramed Pharmaceuticals Inc. (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Oramed</span></span>&#8221;), pursuant to which Oramed consented, and SCLX Stock Acquisition JV LLC (&#8220;<span style="font-weight:bold"><span style="font-style:italic">SCLX JV</span></span>&#8221;) agreed to (i)&#160;transfer (in one or more series of transfers) up to an aggregate of 60,068,585 shares of common stock, par value $0.0001 per share, of the Company (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Relevant Scilex Shares</span></span>&#8221; and each a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Relevant Scilex Share</span></span>&#8221;) held by SCLX JV, to an account of SCLX JV at a Designated Broker (as defined therein), subject to certain conditions, and (ii)&#160;subsequently to engage in sales of the Relevant Scilex Shares to one or more purchasers in such amounts, at such times, and at such prices as SCLX JV may determine in its sole discretion; <span style="font-style:italic">provided that</span>, the net cash proceeds of any sale of the Relevant Scilex Shares shall be distributed in accordance with the Specified Order (as defined below) (any such transfers, sales, distributions and the payment of the Specified Fee (as defined below), collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Subject Transactions</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Tranche A Consent Letter and the Tranche B Consent Letters (as defined below), (a) on each date on which scheduled principal installments are due in accordance with that certain Senior Secured Promissory Note, dated as of September 21, 2023, issued by the Company to Oramed (as amended, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Tranche A Note</span></span>&#8221;), to the extent the Company fails to pay the scheduled principal installment on such date, SCLX JV shall deliver the shortfall of any such scheduled principal installment on the Tranche A Note to Oramed from the Net Cash Proceeds (as defined therein) from such Subject Transactions, and (b) on each Amortization Date (as defined in that certain Tranche B Senior Secured Convertible Note, dated as of October 8, 2024, issued by the Company to Oramed, Nomis Bay Ltd, BPY Limited and 3i, LP (collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Tranche B Noteholders</span></span>&#8221;, and the note, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Tranche B Notes</span></span>&#8221;), to the extent the Company fails to pay the Amortization Amount (as defined in the Tranche B Notes) to the Tranche B Noteholders, SCLX JV shall deliver the shortfall of any such required Amortization Amount to the Tranche B Noteholders from the Net Cash Proceeds (as defined therein) from such Subject Transactions. The parties agreed that amortization payments under the Tranche A Note and the Tranche B Notes are to be made in the following sequence (such order, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Specified Order</span></span>&#8221;): (i) first, to Oramed, an aggregate amount equal to $13,239,205 in satisfaction of the principal payment due on December&#160;21, 2024 under the Tranche A Note, (ii)&#160;second, to the Tranche B Noteholders an aggregate amount equal to and in satisfaction of the Amortization Redemption Price (as defined in the Tranche B Notes) due on January 2, 2025, and (iii)&#160;third, to Oramed until the remaining outstanding principal amount and accrued and unpaid interest under the Tranche A Note is paid in full (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Remaining Tranche A Payment</span></span>&#8221;). In addition, SCLX JV agreed to pay the Designated Broker a sales commission equal to 2.5% of the gross proceeds from the sale of a Relevant Scilex Share (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Specified Fee</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration for the consent to the Subject Transactions, and to further secure the complete timely payment, performance and discharge in full, as the case may be, of all of the Obligations (as defined in the Consent Letters), SCLX JV granted to Acquiom Agency Services LLC (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Agent</span></span>&#8221;) as the agent a security interest in and to, a lien, among other things, on the proceeds of the Relevant Scilex Shares (collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">SCLX Shares Collateral</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Tranche A Consent Letter does not purport to be complete and is qualified in its entirety by reference to the full text of this agreement, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tranche B Consent Letters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;9, 2024, the Company entered into a Consent Letter with each of (i)&#160;Nomis Bay Ltd and BPY Limited (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Nomis Bay Consent Letter</span></span>&#8221;), (ii) Oramed (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Oramed Consent </span></span><span style="font-weight:bold"><span style="font-style:italic">Letter</span></span>&#8221;) and (iii) 3i, LP (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">3i Consent Letter</span></span>&#8221; and, together with the Nomis Bay Consent Letter and the Oramed Consent Letter, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Tranche B Consent Letters</span></span>&#8221; and together with the Tranche A Consent Letter, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Consent Letters</span></span>&#8221;), respectively, pursuant to which the Tranche B Noteholders consented to, and SCLX JV agreed to, the Subject Transactions. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company and the Tranche B Noteholders further agreed that, from and after the satisfaction of the Remaining Tranche A Payment, the amortization payments under the Tranche A Note and the Tranche B Notes shall be distributed to the Tranche B Noteholders in an aggregate amount equal to and in satisfaction of the Amortization Redemption Price due on April 1, 2025 and the Amortization Redemption Price due on July 1, 2025 (each as defined in the Tranche B Notes). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the Nomis Bay Consent Letter, the Oramed Consent Letter and the 3i Consent Letter do not purport to be complete and are qualified in their entireties by reference to the full text of these agreements, a copy of each of which is filed herewith as Exhibit 10.2, Exhibit 10.3 and Exhibit 10.4, respectively, and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d905678dex101.htm">Consent under Securities Purchase Agreement and Senior Secured Promissory Note, dated December&#160;9, 2024, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d905678dex102.htm">Consent under Securities Purchase Agreement and Tranche B Senior Secured Convertible Note, dated December&#160;9, 2024, by and among Scilex Holding Company, Nomis Bay Ltd, BPY Limited, SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d905678dex103.htm">Consent under Securities Purchase Agreement and Tranche B Senior Secured Convertible Note, dated December&#160;9, 2024, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d905678dex104.htm">Consent under Securities Purchase Agreement and Tranche B Senior Secured Convertible Note, dated December&#160;9, 2024, by and among Scilex Holding Company, 3i, LP, SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of&#160;1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">SCILEX HOLDING COMPANY</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jaisim Shah</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer&#160;&amp; President</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December&#160;10, 2024 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d905678dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;9, 2024 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SCLX Stock Acquisition JV </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Rd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Xiao Xu </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Rd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Stephen Ma </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EMAIL </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">RE:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consent under Securities Purchase Agreement and Senior Secured Promissory Note (this &#147;<U>Consent
Letter</U>&#148;) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to (i)&nbsp;that certain Securities Purchase Agreement, dated as of September&nbsp;21, 2023 (the &#147;<U>SPA</U>&#148;),
between Scilex Holding Company, a Delaware corporation (the &#147;<U>Company</U>&#148;), Oramed Pharmaceuticals Inc., a Delaware corporation (&#147;<U>Oramed</U>&#148;) as the initial purchaser (the &#147;<U>Initial Purchaser</U>&#148;), and Acquiom
Agency Services LLC, as Agent (&#147;<U>Agent</U>&#148;), (ii) that certain Senior Secured Promissory Note, dated as of September&nbsp;21, 2023 (the &#147;<U>Note</U>&#148;), issued by Scilex to Oramed, as Holder (&#147;<U>Holder</U>&#148;), (iii)
that certain Amended and Restated Security Agreement, dated as of October&nbsp;8, 2024 (the &#147;<U>Security Agreement</U>&#148;), among the Company, SCLX Stock Acquisition JV LLC (&#147;<U>SCLX JV</U>&#148;) (as defined below) and the other
subsidiaries of the Company party thereto and Acquiom Agency Services LLC, a Colorado limited liability company, as the collateral agent (the &#147;<U>Agent</U>&#148;) for the holders of the Note and all Additional Notes (as defined in the Note),
their endorsees, transferees and assigns (collectively with the Agent, the &#147;<U>Secured Parties</U>&#148;) and as collateral agent for the holders of certain Tranche B Notes (as defined therein), (iv) that certain Limited Liability Company
Agreement of SCLX JV , dated as of September&nbsp;21, 2023, by and among SCLX JV and the members named therein (the &#147;<U>LLC Agreement</U>&#148;), (v) that certain Tranche B Senior Secured Convertible Note, dated as of October&nbsp;8, 2024 (the
&#147;<U>Tranche B Note</U>&#148; and together with the Tranche B Senior Secured Convertible Notes, dated as of such date and held by each other holder thereof, the &#147;<U>Tranche B Notes</U>&#148;), issued by Scilex to Oramed, and (vi)&nbsp;all
related Transaction Documents, as defined in the SPA.&nbsp;Capitalized terms used but not defined herein are used with the respective meanings assigned to them in the SPA, the Note, or the Security Agreement, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, if the Company is not able to satisfy its payment obligations pursuant <U>Section</U><U></U><U>&nbsp;2(e)</U> of the Note in
cash when due, an Event of Default will occur under the Note (the &#147;<U>Anticipated Events of Default</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, if
an Event of Default occurs under the Note, the Agent and the Holders will be entitled to exercise certain secured creditor remedies pursuant to the Note and the other Transaction Documents, including, without limitation by recourse against the
assets of SCLX JV as a grantor under the Security Agreement; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the parties desire to establish a cash reserve from the proceeds of the sale
of certain assets of SCLX JV (the &#147;<U>Cash Reserve</U>&#148;) in order to obtain in advance, if needed, a limited waiver of certain Anticipated Events of Default that may occur from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, the parties hereto hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1 <U>Limited Waiver of Certain Anticipated Events of Default</U>. If an Anticipated Event of Default occurs, to the extent SCLX
JV pays the balance of the unpaid portion of the applicable scheduled principal installment of the Note to the Holder on such applicable due date from the Cash Reserve, such Anticipated Event of Default for any such failure by the Company to pay
such scheduled principal installment directly to the Holder on such payment date shall be automatically waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2 <U>Limited
Consent and Agreement to Engage in Subject Transactions</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Holder hereby consents, and SCLX JV hereby agrees to,
(x)&nbsp;transfer (in one or more series of transfers, in each case, after the sale of any Relevant Scilex Share(s)) up to an aggregate of 60,068,585 shares of common stock, par value $0.0001 per share, of the Company (the &#147;<U>Relevant Scilex
Shares</U>&#148; and each a &#147;<U>Relevant Scilex Share</U>&#148;) to an account of SCLX JV at the brokerage firm Curvature Securities LLC or such other brokerage firm or firms as SCLX JV may select, so long as the fee of any such brokerage firm
does not exceed the Specified Fee, no exclusivity is afforded to such brokerage firm and the prior written consent of the Required Holders has been obtained therefor (each such account, a &#147;<U>Designated Brokerage Account</U>&#148; and each such
firm, a &#147;<U>Designated Broker</U>&#148;), only to the extent that SCLX JV has given irrevocable instruction to the applicable Designated Broker that any and all net cash proceeds from any transactions within such Designated Brokerage Account
shall be transferred immediately to the Designated Proceeds Account (as defined below) and (y)&nbsp;to engage in sales of the Relevant Scilex Shares to any one or more purchasers in such amounts, at such times, and at such prices as SCLX JV may
determine in its sole discretion; <U>provided</U>, <U>that</U>, the net cash proceeds of any sale of the Relevant Scilex Shares (which the parties hereto acknowledge and agree shall be an amount per share equal to (i)&nbsp;the gross proceeds from
such sale paid by a purchaser in respect of a Relevant Scilex Share <I>minus</I> (ii)&nbsp;solely the Specified Fee (as defined below) payable in respect of such Relevant Scilex Share (such net amount, the &#147;<U>Net Cash Proceeds</U>&#148;))
shall be immediately transferred to that certain account of SCLX JV at Bank of America, N.A. ending in 3707 (the &#147;<U>Designated Proceeds Account</U>&#148;) and thereafter subject to application pursuant to <U>Section</U><U></U><U>&nbsp;4</U>
(any such transfers, sales, and the payment of the Specified Fee pursuant to this clause (y), collectively with clause (x), the &#147;<U>Subject Transactions</U>&#148;). For the avoidance of doubt, the Subject Transactions shall not be subject to
Section&nbsp;2(g)(i) of the Note. In connection with such consent and agreement, the Holder hereby: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) agrees, and hereby
directs the Agent to agree, that solely upon the substantially simultaneous consummation of the Subject Transactions including the deposit of the Net Cash Proceeds into the Designated Proceeds Account, that any security interest and lien that Agent
and Holder may have solely in the Relevant Scilex Shares shall be released; provided that the security interest and lien in the Net Cash Proceeds of such Relevant Scilex Shares from the Subject Transactions shall not be released; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) agrees, and the Holder hereby directs the Agent to execute and deliver to the Company or SCLX JV, as applicable, any such
additional documents, instruments or releases as are reasonably requested and necessary to give effect to the Subject Transactions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) subject to the truth and accuracy of the representations set forth in
Section&nbsp;7(h) below, acknowledges that SCLX JV has agreed to pay (and may in the future agree to pay) one or more Designated Brokers a sales commission not to exceed 2.5% of the gross proceeds from the sale of a Relevant Scilex Share (such fee,
whether paid directly or netted from the gross proceeds of the sale of the Relevant Scilex Shares, the &#147;<U>Specified Fee</U>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) by consenting to SCLX JV engaging in the consummation of the Subject Transactions, waives any violation of: (A)&nbsp;the
covenants set forth in Section&nbsp;7(a)(vii) and Section&nbsp;7(e) of the Note, in Section&nbsp;4(dd) of the Security Agreement and in Section&nbsp;4.13(b) of the SPA, in each case solely as each such provision applies to the Subject Transactions;
and (B)&nbsp;without limitation of Section&nbsp;5, any provision in the Transaction Documents that requires the Company or SCLX JV, as applicable, to enter into any document or agreement pledging to the Secured Parties or granting the Secured
Parties (or any of them) control over any Designated Brokerage Account (but not, for the avoidance of doubt, the Designated Proceeds Account) or otherwise taking action to grant or perfect a security interest in favor of the Secured Parties (or any
of them) in any Designated Brokerage Account (but not, for the avoidance of doubt, the Designated Proceeds Account) or the Relevant Scilex Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The foregoing limited consent and limited waivers contained in <U>Sections 1</U> and <U>2</U> (i) are <FONT
STYLE="white-space:nowrap">one-time</FONT> consent and waivers, (ii)&nbsp;are expressly limited to the consent and waivers described above in <U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2</U>, (iii) shall not be deemed or
otherwise construed to constitute a consent to any other extension, whether or not similar to the consents and waivers described above in <U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2,</U> and (iv)&nbsp;shall not operate as
a waiver of any right, power or remedy of the Agent or the Holder under the Note, any other Transaction Document or any other document, instrument or agreement executed in connection therewith, nor constitute a waiver, release or modification of the
Company&#146;s or any Subsidiary&#146;s obligations to comply with all terms and conditions of the Note and other Transaction Documents. The Agent and the Holder have granted the limited consent and limited waivers set forth in
<U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2</U> in this particular instance and in light of the facts and circumstances that presently exist, and the grant of such consent shall not constitute a course of dealing or
impair the Agent&#146;s or any Holder&#146;s right to withhold any similar consent or waiver in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3
<U>Distribution Consent and Agreement</U>. In furtherance of the Subject Transactions, the Holder hereby consents pursuant to (a)&nbsp;Sections 7.07(d) and 7.07(e) of the LLC Agreement, to SCLX JV entering into the Subject Transactions; and
(b)&nbsp;Section&nbsp;6.01(a) of the LLC Agreement), to SCLX JV, and SCLX JV agrees to, make a distribution of the Net Cash Proceeds from the Subject Transactions to its sole member, SCLX DRE, and the subsequent distribution by SCLX DRE to its sole
member, the Company, for the Company to make a payment in respect of the Note as set forth in <U>Section</U><U></U><U>&nbsp;4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4 <U>Proceeds of Subject Transaction</U>. Subject to the terms of the Intercreditor Agreement, SCLX JV, the Company and the
Holder hereby agree that (a)&nbsp;on each date on which scheduled principal installments are due in accordance with Section&nbsp;2(e) of the Note, to the extent the Company fails to pay the scheduled principal installment on such date, SCLX JV shall
deliver (directly, or via distribution to the Company for such purpose) on such date (each such payment due date, a &#147;<U>Tranche A Payment Date</U>&#148;) the shortfall of any such scheduled principal installment on the Note to the Holder from
the Net Cash Proceeds from such Subject Transactions, and (b)&nbsp;on each Amortization Date (as defined in the Tranche B Notes), to the extent the Company fails to pay the Amortization Amount (as defined in the Tranche B Notes) to the Holders of
the Tranche B Notes, SCLX JV shall deliver (directly, or via distribution to the Company for such purpose) on such date (each such payment due date, a &#147;<U>Tranche B Payment Date</U>&#148;), the shortfall
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of any such required Amortization Amount to the Holder from the Net Cash Proceeds from such Subject Transactions. For the avoidance of doubt, the parties acknowledge and agree that amortization
payments under the Tranche A Notes and Tranche B Notes are to be made in the following sequence and in the event that an amortization payment is not made on a Tranche A Payment Date or a Tranche B Payment Date, as applicable, in the full amount
thereof in accordance with the below, SCLX JV shall not make a subsequently due amortization payment pursuant to this <U>Section</U><U></U><U>&nbsp;4</U> until the Company or SCLX JV has first completed all prior amortization payments that remain
unsatisfied: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I><U>first</U></I>, to Holder, an aggregate amount equal to $13,239,205 in satisfaction of the principal
payment due on December&nbsp;21, 2024 under Section&nbsp;2(e) of the Note (the &#147;<U>December Tranche A Payment</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>second</I>, from and after the satisfaction of the December Tranche A Payment, to the holders of Tranche B Notes an
aggregate amount equal to and in satisfaction of the Amortization Redemption Price (as defined in the Tranche B Note) due on January&nbsp;2, 2025 (the &#147;<U>January Tranche B Payment</U>&#148;);and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>third</I>, from and after the satisfaction of the January Tranche B Payment, to the Holder until the remaining
outstanding principal amount and accrued and unpaid interest under the Note is paid in full in accordance with Section&nbsp;2(e) of the Note (the &#147;<U>Final Tranche A Payment</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Holder shall not be entitled to receive and SCLX JV will not be required to deliver, proceeds of any sale of
Relevant Scilex Shares in excess of the aggregate amount required to repay the remaining outstanding principal amount and accrued and unpaid interest under the Note. The Net Cash Proceeds from the sale of the Relevant Scilex Shares may not be
applied or utilized for any purpose other than servicing the payments of principal and interest due under the Note and the Tranche B Notes as expressly set forth in this Section&nbsp;4. The payments under the Note using proceeds of the Subject
Transactions and required under this Section&nbsp;4 shall be payable without premium or penalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary
or any grace, cure or similar period that may be set forth in the Transaction Documents and without limitation of any rights of the Agent pursuant to that certain Deposit Account Control Agreement, dated as of March&nbsp;12, 2024, among SCLX JV, the
Agent and Bank of America, N.A., the parties acknowledge and agree that if the Company fails to make any payment required to be made pursuant to this <U>Section</U><U></U><U>&nbsp;4</U> on a Tranche A Payment Date or a Tranche B Payment Date, as
applicable, then, effective automatically as of 12:01 a.m., eastern on the next calendar day and without the requirement of any further action by SCLX JV, the Company or any of their respective affiliates, the Agent has the full right, power and
authority to cause and is, by virtue of this Consent Letter together with contemporaneously delivered consents of the Tranche A Holder and the other holders of Tranche B Notes, directed to cause such amortization payment to be made (to the fullest
extent of the funds available therefore) from the Cash Reserve in the Designated Proceeds Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5 <U>Grant of Security
Interest</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In consideration for the consent to the Subject Transaction contained herein, and to further secure the
complete timely payment, performance and discharge in full, as the case may be, of all of the Obligations, SCLX JV hereby unconditionally and irrevocably pledges, grants and hypothecates to the Agent (on behalf and for the benefit of the Secured
Parties) a security interest in and to, a lien upon and a right of <FONT STYLE="white-space:nowrap">set-off</FONT> against all of their respective right, title and interest of whatsoever kind and nature in and to the Proceeds of the Relevant Scilex
Shares, in whatever form, including without limitation Payment Intangibles, and Supporting Obligations (collectively, the &#147;<U>SCLX Shares Collateral</U>&#148;). SCLX JV and the Company hereby consent and agree to (and agree to cooperate with)
the Agent, at the direction of the Holder, taking any and all further action to perfect a security interest in favor of the Secured Parties, including the filing of <FONT STYLE="white-space:nowrap">UCC-1</FONT> financing statements and/or entering
into a control agreement with respect to the SCLX Shares Collateral. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) SCLX JV and the Company hereby agree that they shall cause to be granted
to the Agent (on behalf of and for the benefit of the Secured Parties) a security interest in the Relevant Scilex Shares and/or the Designated Brokerage Account (as specified by the Required Holders and the Tranche A Holder); <U>provided</U>
<U>that, in each case,</U> such security interest may be limited to the extent necessary to ensure that such security interest or the granting thereof does not violate applicable law or impose upon SCLX JV or the Company additional burdensome filing
requirements that exceed the benefit thereof, in each case, as reasonably determined by SCLX JV and/or the Company upon the advice of outside counsel and following good faith consultation with the Holder and the Required Holders (as defined in the
Tranche B Notes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6 <U>Agent Direction</U>. The Holder constituting the Required Holders under the SPA hereby authorizes and
directs the Agent to execute this Consent Letter and to enter into any documentation reasonably required by <U>Section</U><U></U><U>&nbsp;4</U> above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7 <U>Representations and Warranties</U>. In order to induce the Agent and the Holder to enter into this Consent Letter, the
Company hereby represents and warrants as of the date hereof that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) [reserved]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Company has the full right, power and authority to enter into and execute this Consent Letter and to perform all its
obligations hereunder and under the Note and the Transaction Documents, as modified hereby and SCLX JV has the full right, power and authority to perform the Subject Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the execution and delivery of this Consent Letter has been duly and validly authorized by all necessary action on the part
of the Company, and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with the terms hereof, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other Laws of general application affecting enforcement of creditors&#146; rights generally; and (ii)&nbsp;as limited by Laws relating to the availability of specific performance, injunctive relief or other
equitable remedies; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) neither the execution and delivery of this Consent Letter, nor the taking of any actions
contemplated hereby and the performance of the obligations hereunder or the Subject Transactions by the Company, SCLX JV or any other Subsidiary, does or will, with or without the giving of notice, lapse of time or both, (i)&nbsp;violate or
constitute a default, event of default, or event creating a right of acceleration, termination or cancellation of any obligation under any term or provision of any agreement, credit facility, debt or other instrument evidencing Company or Subsidiary
Indebtedness (after giving effect to any prior or concurrent consents or waivers under any such agreement, credit facility, debt or other instrument to which the Company or such Subsidiary is a party or otherwise subject, copies of which consents or
waivers have been furnished by the Company to the Agent prior to the execution of this Consent Letter); or (ii)&nbsp;violate any rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) no authorization, consent, approval, license, exemption of or filing or
registration with any governmental authority, is or will be necessary for the execution, delivery and performance by the Company of its obligations under this Consent Letter or the performance by SCLX JV of the Subject Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) immediately prior to and after giving effect to this Consent Letter, no Default or Event of Default exists and is
continuing on the date hereof and no Event of Default could reasonably be expected to occur as a result of the Subject Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the Company has furnished to the Holder a statement setting forth its (i)&nbsp;authorized share capitalization and
(ii)&nbsp;issued and outstanding share capitalization, in each case as of the date hereof, and the sale of all or a portion of the Relevant Scilex Shares shall not constitute an increase to the Company&#146;s outstanding share capital; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8201;(i) other than the Specified Fee (if and to the extent it becomes payable in connection with the sale of Relevant
Scilex Shares), no broker, finder, agent or investment banker is entitled to any brokerage, finder&#146;s or other fee or commission in connection with the Subject Transactions from the Company, SCLX JV or any other Subsidiary (any such fees or
commissions, &#147;<U>Broker Fees</U>&#148;), (ii) other than any Designated Broker, no broker, finder, agent or investment banker has been engaged by the Company, its Subsidiaries or any person acting on their behalf in connection with the Subject
Transactions and the Company has furnished to the Agent copies of all agreements or arrangements with any Designated Broker as of the date hereof, and (iii)&nbsp;no Broker Fees have been paid or are due and owing to any Designated Broker or any
other broker, finder, agent or investment banker in connection with the Subject Transactions (as defined in that certain Waiver and Consent Letter, dated January&nbsp;29, 2024, by and among the parties hereto) (the &#147;<U>Original Subject
Transaction</U>&#148;) and neither any Designated Broker or any other broker, finder, agent or investment banker shall be entitled to any Broker Fee in connection with the Original Subject Transaction and the Designated Broker shall be entitled
solely to the Specified Fee in respect of the Relevant Scilex Shares (as defined herein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8 <U>Affirmation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as expressly consented to pursuant to <U>Section</U><U></U><U>&nbsp;1</U> hereof, the Company hereby expressly
reaffirms, as of the date hereof, all its covenants and agreements contained in the Note and each Transaction Document and agrees that none of its covenants and agreements set forth in the Note or any other Transaction Document shall be reduced or
limited by the execution and delivery of this Consent Letter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company (on behalf of itself and its Subsidiaries)
hereby (i)&nbsp;affirms that each of the Liens granted in or pursuant to the Security Documents are valid and subsisting, and (ii)&nbsp;agrees that this Consent Letter and all documents executed in connection herewith shall in no manner impair or
otherwise adversely affect any of the Liens granted in or pursuant to the Security Documents and such Liens continue unimpaired with the same priority to secure repayment of all Obligations in accordance with the Transaction Documents, whether
heretofore or hereafter incurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company (on behalf of itself and its Subsidiaries) hereby (i)&nbsp;acknowledges
and agrees that the Holder has no liability or obligation to pay the Specified Fees or any other Broker Fees and (ii)&nbsp;indemnifies the Holder against and holds it harmless from any and all liabilities (including, without limitation, reasonable
attorneys&#146; fees and disbursements paid or incurred in connection with any such liabilities) for the Specified Fees and any other Broker Fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9 <U>Expiration</U>. If all of the Relevant Scilex Shares have not been sold
prior to July&nbsp;1, 2025 (the &#147;<U>Expiration Date</U>&#148;), then on the Expiration Date the consents set forth in <U>Section</U><U></U><U>&nbsp;2</U> shall expire and be of no further force and effect with respect to such remaining unsold
Relevant Scilex Shares, and the Company, its Subsidiaries (including SCLX JV) and such remaining unsold Relevant Scilex Shares shall again be subject to all restrictions and limitations pursuant to the Transaction Documents and the organizational
documents of the Company and its Subsidiaries (including SCLX JV) to which the Relevant Scilex Shares (or any proposed transfer thereof) were subject prior to giving effect to the consents set forth herein (other than with respect to any transfers
or related transactions required to comply with the terms of this <U>Section</U><U></U><U>&nbsp;8</U> on and following the Expiration Date). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10 <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Section headings in this Consent Letter are included herein for convenience of reference only and shall not constitute a
part of this Consent Letter for any other purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This Consent Letter may be executed with counterpart signature
pages or in any number of counterparts, each of which shall be deemed to be an original, but all such separate counterparts shall together constitute but one and the same agreement. In proving this Consent Letter or any other Transaction Document in
any judicial proceedings, it shall not be necessary to produce or account for more than one such counterpart signed by the party against whom such enforcement is sought. Any signatures hereto delivered by electronic transmission shall be deemed an
original signature hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No waiver or modification hereof or of any agreement referred to herein shall be binding or
enforceable unless in writing and signed by all of the parties hereto or thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) From and after the date on which
this Consent Letter shall be effective, the term &#147;Transaction Documents&#148; in the Note and the other Note Documents shall include, without limitation, this Consent Letter and any agreements, instruments and other documents executed and/or
delivered in connection herewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) THE TERMS AND PROVISIONS OF SECTION&nbsp;9(D) (GOVERNING LAW) OF THE NOTE ARE HEREBY
INCORPORATED HEREIN BY REFERENCE AND SHALL APPLY TO THIS CONSENT LETTER MUTATITIS MUTANDIS AS IF FULLY SET FORTH HEREIN. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company has agreed to reimburse Holder and the Agent upon the execution of this Consent Letter for its reasonable and
documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal costs, fees and expenses actually incurred by the Agent or the Holder in connection with this Consent Letter and the Subject Transactions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ORAMED PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Nadav Kidron</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Nadav Kidron</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Avi Gabay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Avi Gabay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address for Notice:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">1185 Avenue of the Americas,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Third Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10036</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: Nadav Kidron; Avi Gabay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: nadav@oramed.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">&#8195;&#8195;&#8195;avi@oramed.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">with a copy (which shall not constitute notice) to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Proskauer Rose LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Eleven Times Square</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10036</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Ehud Barak; James Gerkis; Grant Darwin;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Philip Kaminski</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> ebarak@proskauer.com;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jgerkis@proskauer.com; gdarwin@proskauer.com;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">pkaminski@proskauer.com</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Consent Letter Dated December</I><I></I><I>&nbsp;9, 2024</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCLX STOCK ACQUISITION JV LLC </B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Xiao Xu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Xiao Xu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sole Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SCLX Stock Acquisition JV</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">960 San Antonio Rd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Palo Alto, CA 94303</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: Xiao Xu</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Consent Letter Dated December</I><I></I><I>&nbsp;9, 2024</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCILEX HOLDING COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Stephen Ma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Stephen Ma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">960 San Antonio Rd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Palo Alto, CA 94303</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attention: Stephen Ma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Telephone: <FONT STYLE="white-space:nowrap">(408)891-8341</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: <U>sma@scilexholding.com</U></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Consent Letter Dated December</I><I></I><I>&nbsp;9, 2024</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ACQUIOM AGENCY SERVICES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Beth Cesari</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Beth Cesari</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Executive Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address for Notice:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">950 17<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Street, Suite 1400</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Denver, CO 80202</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: <U>bcesari@srsacquiom.com</U></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Consent Letter Dated December</I><I></I><I>&nbsp;9, 2024</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d905678dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;9, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SCLX Stock Acquisition JV </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Rd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Xiao Xu </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Rd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Stephen Ma </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EMAIL </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RE: Consent under Securities Purchase
Agreement and Tranche B Senior Secured Convertible Note (this &#147;<U>Consent Letter</U>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to (i)&nbsp;that certain Securities Purchase Agreement, dated as of October&nbsp;7, 2024 (the &#147;<U>SPA</U>&#148;),
between Scilex Holding Company, a Delaware corporation (the &#147;<U>Company</U>&#148;), each investor listed on the Schedule of Buyers attached thereto, (the &#147;<U>Buyers</U>&#148;) and Acquiom Agency Services LLC, a Colorado limited liability
company (&#147;<U>Acquiom</U>&#148;), as collateral agent, (ii)&nbsp;that certain Tranche B Senior Secured Convertible Note, dated as of October&nbsp;8, 2024 (the &#147;<U>Note</U>&#148;, and together with the Tranche B Senior Secured Convertible
Notes, dated as of such date and held by each other holder thereof, the &#147;<U>Tranche B Notes</U>&#148;), issued by Scilex to the undersigned, as Holder (&#147;<U>Holder</U>&#148;), (iii) that certain Amended and Restated Security Agreement,
dated as of October&nbsp;8, 2024 (the&nbsp;&#147;<U>Security Agreement</U>&#148;), among the Company, SCLX Stock Acquisition JV (&#147;<U>SCLX JV</U>&#148;) and the other subsidiaries of the Company party thereto and Acquiom, as the collateral agent
(the &#147;<U>Agent</U>&#148;) for the holders of the Note and all Other Notes (as defined in the Note), their endorsees, transferees and assigns (collectively with the Agent, the &#147;<U>Secured Parties</U>&#148;) and as collateral agent for the
holders of certain Tranche A Notes (as defined therein), (iv) that certain Senior Secured Promissory Note, dated as of September&nbsp;21, 2023 (the &#147;<U>Tranche A Note</U>&#148;), issued by Scilex to Oramed Pharmaceuticals Inc., as holder (the
&#147;<U>Tranche A Holder</U>&#148;) and (v)&nbsp;all related Transaction Documents, as defined in the SPA.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used but not
defined herein are used with the respective meanings assigned to them in the SPA, the Note, or the Security Agreement, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, if the Company is not able to satisfy its payment obligations pursuant to Section&nbsp;14 of the Tranche B Notes in cash when
due, an Event of Default will occur under the Tranche B Notes (the &#147;<U>Anticipated Events of Default</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, if
an Event of Default occurs under the Note, the Agent and the Holders will be entitled to exercise certain secured creditor remedies pursuant to the Note and the other Transaction Documents, including, without limitation by recourse against the
assets of SCLX JV as a grantor under the Security Agreement; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the parties desire to establish a cash reserve from the proceeds of the sale
of certain assets of SCLX JV (the &#147;<U>Cash Reserve</U>&#148;) in order to obtain in advance, if needed, a limited waiver of certain Anticipated Events of Default that may occur from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, the parties hereto hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1 <U>Limited Waiver of Certain Anticipated Events of Default</U>. If an Anticipated Event of Default occurs, to the extent SCLX
JV pays the balance of the unpaid portion of the applicable Amortization Amount (as defined in the Notes) to the Holder (solely to the extent the Holder has no obligation to turn over such amounts to any other Person pursuant to the Intercreditor
Agreement at such time) on such applicable Amortization Date from the Cash Reserve, such Anticipated Event of Default for any such failure by the Company to pay such Amortization Amount directly to the Holder on such Amortization Date shall be
automatically waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2 <U>Limited Consent and Agreement to Engage in Subject Transactions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Holder hereby consents, and SCLX JV hereby agrees, to (x)&nbsp;transfer (in one or more series of transfers, in each
case after the sale of any Relevant Scilex Share(s)) up to an aggregate of 60,068,585 shares of common stock, par value $0.0001 per share, of the Company (the &#147;<U>Relevant Scilex Shares</U>&#148; and each a &#147;<U>Relevant Scilex
Share</U>&#148;) to an account of SCLX JV at the brokerage firm Curvature Securities LLC or such other brokerage firm or firms as SCLX JV may select , so long as the fee of any such brokerage firm does not exceed the Specified Fee, no exclusivity is
afforded to such brokerage firm and the prior written consent of the Required Holders has been obtained therefor (each such account, a &#147;<U>Designated Brokerage Account</U>&#148; and each such firm, a &#147;<U>Designated Broker</U>&#148;), only
to the extent that SCLX JV has given irrevocable instruction to the applicable Designated Broker that any and all net cash proceeds from any transactions within such Designated Brokerage Account shall be transferred immediately to the Designated
Proceeds Account (as defined bellow) and (y)&nbsp;to engage in sales of the Relevant Scilex Shares to any one or more purchasers in such amounts, at such times, and at such prices as SCLX JV may determine in its sole discretion; <U>provided</U>,
<U>that</U>, the net cash proceeds of any sale of the Relevant Scilex Shares (which the parties hereto acknowledge and agree shall be an amount per share equal to (i)&nbsp;the gross proceeds from such sale paid by a purchaser in respect of a
Relevant Scilex Share <I>minus</I> (ii)&nbsp;solely the Specified Fee (as defined below) payable in respect of such Relevant Scilex Share (such net amount, the &#147;<U>Net Cash Proceeds</U>&#148;)) shall be immediately transferred to that certain
account of SCLX JV at Bank of America, N.A. ending in 3707 (the &#147;<U>Designated Proceeds Account</U>&#148;) and thereafter subject to application pursuant to <U>Section</U><U></U><U>&nbsp;3</U> below (any such transfers, sales and the payment of
the Specified Fee pursuant to this clause (y), collectively, with clause (x), the&nbsp;&#147;<U>Subject Transactions</U>&#148;). For the avoidance of doubt, the Subject Transactions shall not be subject to the provisions of Section&nbsp;9 or
Section&nbsp;10 of the Note. In connection with such consent and agreement, the Holder hereby: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) agrees, and hereby
directs the Agent to agree, that solely upon the substantially simultaneous consummation of the Subject Transactions including the deposit of the Net Cash Proceeds into the Designated Proceeds Account, that any security interest and lien that Agent
and Holder may have solely in the Relevant Scilex Shares shall be released; provided that the security interest and lien in the Net Cash Proceeds of such Relevant Scilex Shares from the Subject Transactions shall not be released. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) agrees, and the Holder hereby directs the Agent to execute and deliver to the Company or SCLX JV, as applicable, any such
additional documents, instruments or releases as are reasonably requested and necessary to give effect to the Subject Transactions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) acknowledges that SCLX JV has agreed to pay (and may in the future
agree to pay) one or more Designated Brokers a sales commission not to exceed 2.5% of the gross proceeds from the sale of a Relevant Scilex Share (such fee, whether paid directly or netted from the gross proceeds of the sale of the Relevant Scilex
Shares, the &#147;<U>Specified Fee</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) by consenting to SCLX JV engaging in the consummation of the Subject
Transactions, waives any violation of: (A)&nbsp;the covenants set forth in Section&nbsp;17(e) and (f)&nbsp;of the Note, in Section&nbsp;4(dd) of the Security Agreement and in Section&nbsp;4(p) of the SPA, in each case solely as each such provision
applies to the Subject Transactions, (B)&nbsp;without limitation of <U>Section</U><U></U><U>&nbsp;4</U>, any provision in the Transaction Documents that requires the Company or SCLX JV, as applicable, to enter into any document or agreement pledging
to the Secured Parties or granting the Secured Parties (or any of them) control over any Designated Brokerage Account (but not, for the avoidance of doubt, the Designated Proceeds Account) or otherwise taking action to grant or perfect a security
interest in favor of the Secured Parties (or any of them) in any Designated Brokerage Account (but not, for the avoidance of doubt, the Designated Proceeds Account) or the Relevant Scilex Shares, and (C)&nbsp;agrees that, subject to compliance with
the terms of this Consent and Demand Letter, including as to the application of proceeds in accordance with <U>Section</U><U></U><U>&nbsp;3</U> hereof, any sale of the Relevant Scilex Shares shall not constitute a &#147;Subsequent Placement&#148; or
&#147;Asset Sale&#148; under the Note and the other Transaction Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) So long as the Required Holders pursuant to
the SPA and Note (as defined therein), as applicable, have consented to the Subject Transactions as set forth herein, such consent shall be binding on all Buyers and holders of Securities pursuant to Section&nbsp;9(e) of the SPA and on all existing
and future holders of any Note pursuant to Section&nbsp;20 of the Note, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The foregoing limited consent
and limited waivers contained in <U>Sections 1</U> and <U>2</U> (i) are <FONT STYLE="white-space:nowrap">one-time</FONT> consent and waivers, (ii)&nbsp;are expressly limited to the consent and waivers described above in
<U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2</U>, (iii) shall not be deemed or otherwise construed to constitute a consent to any other extension, whether or not similar to the consents and waivers described above in
<U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2,</U> and (iv)&nbsp;shall not operate as a waiver of any right, power or remedy of the Agent or any Holder under the Note, any other Transaction Document or any other document,
instrument or agreement executed in connection therewith, nor constitute a waiver, release or modification of the Company&#146;s or any Subsidiary&#146;s obligations to comply with all terms and conditions of the Note and other Transaction
Documents. The Agent and the Holder have granted the limited consent and limited waivers set forth in <U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2</U> in this particular instance and in light of the facts and circumstances
that presently exist, and the grant of such consent shall not constitute a course of dealing or impair the Agent&#146;s or any Holder&#146;s right to withhold any similar consent or waiver in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3 <U>Proceeds of Subject Transaction</U>. Subject to the terms of the Intercreditor Agreement, SCLX JV, the Company and the
Holder hereby agree that (a)&nbsp;on each date on which scheduled amortization payments are due on the Tranche A Note, to the extent the Company fails to pay the required amortization payment on such date, SCLX JV shall deliver (directly, or via
distribution to the Company for such purpose) on such date (each such payment due date, a &#147;<U>Tranche A Payment Date</U>&#148;) the shortfall of any such required amortization payment to the Tranche A Holder from the Net Cash Proceeds from such
Subject Transactions, and (b)&nbsp;on each Amortization Date, to the extent the Company fails to pay the Amortization </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Amount (as defined in the Note) to the Holder, SCLX JV shall deliver (directly, or via distribution to the Company for such purpose) on such date (each such payment due date, a &#147;<U>Tranche B
Payment Date</U>&#148;), the shortfall of any such required Amortization Amount to the Holder from the Net Cash Proceeds from such Subject Transactions. For the avoidance of doubt, the parties acknowledge and agree that amortization payments under
the Tranche A Notes and Tranche B Notes are to be made in the following sequence and in the event that an amortization payment is not made on a Tranche A Payment Date or a Tranche B Payment Date, as applicable, in the full amount thereof in
accordance with the below, SCLX JV shall not make a subsequently due amortization payment pursuant to this <U>Section</U><U></U><U>&nbsp;3</U> until the Company or SCLX JV has first completed all prior amortization payments that remain unsatisfied:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>first</I>, to the Tranche A Holder, an aggregate amount equal to $13,239,205 in satisfaction of the principal
payment due on December&nbsp;21, 2024 under Section&nbsp;2(e) of the Tranche A Note (the &#147;<U>December Tranche A Payment</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>second</I>, from and after the satisfaction of the December Tranche A Payment, to the holders of Tranche B Notes an
aggregate amount equal to and in satisfaction of the Amortization Redemption Price (as defined in the Tranche B Note) due on January&nbsp;2, 2025 (the &#147;<U>January Tranche B Payment</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>third</I>, from and after the satisfaction of the January Tranche B Payment, to the Tranche A Holder until the remaining
outstanding principal amount and accrued and unpaid interest under the Tranche A Note is paid in full in accordance with Section&nbsp;2(e) of the Tranche A Note (the &#147;<U>Final Tranche A Payment</U>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>fourth</I>, from and after the satisfaction of the Final Tranche A Payment, to the holders of Tranche B Notes an
aggregate amount equal to and in satisfaction of the Amortization Redemption Price due on April&nbsp;1, 2025 and the Amortization Redemption Price due on July&nbsp;1, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Holder shall not be entitled to receive and SCLX JV will not be required to deliver, proceeds of any sale of
Relevant Scilex Shares in excess of the aggregate amount required to repay the remaining outstanding principal amount and accrued and unpaid interest under the Note. The Net Cash Proceeds from the sale of the Relevant Scilex Shares may not be
applied or utilized for any purpose other than servicing the payments of principal and interest due under the Tranche A Note and the Tranche B Notes as expressly set forth in this <U>Section</U><U></U><U>&nbsp;3</U>. The payments under the Note
using proceeds of the Subject Transactions and required under this <U>Section</U><U></U><U>&nbsp;3</U> shall be payable without premium or penalty (but, for the avoidance of doubt, shall include the payment of the Make-Whole Amount included in any
such Amortization Redemption Price, as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary or any grace, cure or similar period that
may be set forth in the Transaction Documents and without limitation of any rights of the Agent pursuant to that certain Deposit Account Control Agreement, dated as of March&nbsp;12, 2024, among SCLX JV, the Agent and Bank of America, N.A., the
parties acknowledge and agree that if the Company fails to make any payment required to be made pursuant to this <U>Section</U><U></U><U>&nbsp;3</U> on a Tranche A Payment Date or a Tranche B Payment Date, as applicable, then, effective
automatically as of 12:01 a.m., eastern on the next calendar day and without the requirement of any further action by SCLX JV, the Company or any of their respective affiliates, the Agent has the full right, power and authority to cause and is, by
virtue of this Consent Letter together with contemporaneously delivered consents of the Tranche A Holder and the other holders of Tranche B Notes, directed to cause such amortization payment to be made (to the fullest extent of the funds available
therefore) from the Cash Reserve in the Designated Proceeds Account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4 <U>Grant of Security Interest. </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In consideration for the consent to the Subject Transaction contained herein, and to further secure the complete timely
payment, performance and discharge in full, as the case may be, of all of the Obligations, SCLX JV hereby unconditionally and irrevocably pledges, grants and hypothecates to the Agent (on behalf and for the benefit of the Secured Parties) a security
interest in and to, a lien upon and a right of <FONT STYLE="white-space:nowrap">set-off</FONT> against all of their respective right, title and interest of whatsoever kind and nature in and to the Proceeds of the Relevant Scilex Shares, in whatever
form, including without limitation Payment Intangibles and Supporting Obligations (collectively, the &#147;<U>SCLX Shares Collateral</U>&#148;). SCLX JV and the Company hereby consent and agree to (and agree to cooperate with) the Agent, at the
direction of the Required Holders, taking any and all further action to perfect a security interest in favor of the Secured Parties, including the filing of <FONT STYLE="white-space:nowrap">UCC-1</FONT> financing statements and/or entering into a
control agreement with respect to the SCLX Shares Collateral. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) SCLX JV and the Company hereby agree that they shall
cause to be granted to the Agent (on behalf of and for the benefit of the Secured Parties) a security interest in the Relevant Scilex Shares and/or the Designated Brokerage Account (as specified by the Required Holders and the Tranche A Holder);
<U>provided</U> <U>that</U>, in each case, such security interest may be limited to the extent necessary to ensure that such security interest or the granting thereof does not violate applicable law or impose upon SCLX JV or the Company additional
burdensome filing requirements that exceed the benefit thereof, in each case, as reasonably determined by SCLX JV and/or the Company upon the advice of outside counsel and following good faith consultation with the Required Holders and the Tranche A
Note Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5 <U>Agent Direction</U>. The Holder hereby authorizes and directs the Agent to execute this Consent Letter and
to enter into any documentation reasonably required by <U>Section</U><U></U><U>&nbsp;4</U> above. The Holders&#146; authorization and direction pursuant to this Consent Letter, read simultaneously with the authorization and direction by each other
Holder pursuant to their respective consent letters, collectively constitutes an authorization and direction from all the Holders to enter into each such consent letter and any documentation reasonably required by Sections 4 thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6 <U>Representations and Warranties</U>. In order to induce the Agent and the Holder to enter into this Consent Letter, the
Company hereby represents and warrants as of the date hereof that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) neither it nor any other Person acting on its
behalf has provided any of the undersigned Holders or their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the
Company or any of its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Company has the full right, power and authority to enter into and execute this
Consent Letter and to perform all its obligations hereunder and under the Note and the Transaction Documents, as modified hereby, and SCLX JV has the full right, power and authority to perform the Subject Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the execution and delivery of this Consent Letter has been duly and validly authorized by all necessary action on the part
of the Company, and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with the terms hereof, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other Laws of general application affecting enforcement of creditors&#146; rights generally; and (ii)&nbsp;as limited by Laws relating to the availability of specific performance, injunctive relief or other
equitable remedies; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) neither the execution and delivery of this Consent Letter, nor the
taking of any actions contemplated hereby and the performance of the obligations hereunder or the Subject Transactions by the Company, SCLX JV or any other Subsidiary, does or will, with or without the giving of notice, lapse of time or both,
(i)&nbsp;violate or constitute a default, event of default, or event creating a right of acceleration, termination or cancellation of any obligation under any term or provision of any agreement, credit facility, debt or other instrument evidencing
Company or Subsidiary Indebtedness (after giving effect to any prior or concurrent consents or waivers under any such agreement, credit facility, debt or other instrument to which the Company or such Subsidiary is a party or otherwise subject,
copies of which consents or waivers have been furnished by the Company to the Agent prior to the execution of this Consent Letter); or (ii)&nbsp;violate any rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) no authorization, consent, approval, license, exemption of or filing or registration with any governmental authority, is or
will be necessary for the execution, delivery and performance by the Company of its obligations under this Consent Letter or the performance by SCLX JV of the Subject Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) immediately prior to and after giving effect to this Consent Letter, no Event of Default exists and is continuing on the
date hereof and no Event of Default could reasonably be expected to occur as a result of the Subject Transactions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the
Company has furnished to the Holder a statement setting forth its (i)&nbsp;authorized share capitalization and (ii)&nbsp;issued and outstanding share capitalization, in each case as of the date hereof, and the sale of all or a portion of the
Relevant Scilex Shares shall not constitute an increase to the Company&#146;s outstanding share capital; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;(i)
other than the Specified Fee (if and to the extent it becomes payable in connection with the sale of Relevant Scilex Shares), no broker, finder, agent or investment banker is entitled to any brokerage, finder&#146;s or other fee or commission in
connection with the Subject Transactions from the Company, SCLX JV or any other Subsidiary (any such fees or commissions, &#147;<U>Broker Fees</U>&#148;), and (ii)&nbsp;other than any Designated Broker, no broker, finder, agent or investment banker
has been engaged by the Company, its Subsidiaries or any person acting on their behalf in connection with the Subject Transactions and the Company has furnished to the Agent copies of all agreements or arrangements with any Designated Broker, as of
the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7 <U>Affirmation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as expressly consented pursuant to <U>Section</U><U></U><U>&nbsp;1</U> hereof, the Company hereby expressly
reaffirms, as of the date hereof, all its covenants and agreements contained in the Note and each Transaction Document and agrees that none of its covenants and agreements set forth in the Note or any other Transaction Document shall be reduced or
limited by the execution and delivery of this Consent Letter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company (on behalf of itself and its Subsidiaries)
hereby (i)&nbsp;affirms that each of the Liens granted in or pursuant to the Security Documents are valid and subsisting, and (ii)&nbsp;agrees that this Consent Letter and all documents executed in connection herewith shall in no manner impair or
otherwise adversely affect any of the Liens granted in or pursuant to the Security Documents and such Liens continue unimpaired with the same priority to secure repayment of all Obligations in accordance with the Transaction Documents, whether
heretofore or hereafter incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company (on behalf of itself and its Subsidiaries) hereby
(i)&nbsp;acknowledges and agrees that the Holder has no liability or obligation to pay the Specified Fees or any other Broker Fees and (ii)&nbsp;indemnifies the Holder against and holds it harmless from any and all liabilities (including, without
limitation, reasonable attorneys&#146; fees and disbursements paid or incurred in connection with any such liabilities) for the Specified Fees and any other Broker Fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8 <U>Expiration</U>. If all of the Relevant Scilex Shares have not been sold prior to July&nbsp;1, 2025 (the &#147;<U>Expiration
Date</U>&#148;), then on the Expiration Date, the consents set forth in <U>Section</U><U></U><U>&nbsp;2</U> shall expire and be of no further force and effect with respect to such remaining unsold Relevant Scilex Shares, and the Company, its
Subsidiaries (including SCLX JV) and such remaining unsold Relevant Scilex Shares shall again be subject to all restrictions and limitations pursuant to the Transaction Documents and the organizational documents of the Company and its Subsidiaries
(including SCLX JV) to which the Relevant Scilex Shares (or any proposed transfer thereof) were subject prior to giving effect to the consents set forth herein (other than with respect to any transfers or related transactions required to comply with
the terms of this <U>Section</U><U></U><U>&nbsp;8</U> on and following the Expiration Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9 <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Section headings in this Consent Letter are included herein for convenience of reference only and shall not constitute a
part of this Consent Letter for any other purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This Consent Letter may be executed with counterpart signature
pages or in any number of counterparts, each of which shall be deemed to be an original, but all such separate counterparts shall together constitute but one and the same agreement. In proving this Consent Letter or any other Transaction Document in
any judicial proceedings, it shall not be necessary to produce or account for more than one such counterpart signed by the party against whom such enforcement is sought. Any signatures hereto delivered by electronic transmission shall be deemed an
original signature hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No waiver or modification hereof or of any agreement referred to herein shall be binding or
enforceable unless in writing and signed by all of the parties hereto or thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) From and after the date on which
this Consent Letter shall be effective, the term &#147;Transaction Documents&#148; in the Note and the other Note Documents shall include, without limitation, this Consent Letter and any agreements, instruments and other documents executed and/or
delivered in connection herewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) THE TERMS AND PROVISIONS OF SECTION&nbsp;31 (GOVERNING LAW) OF THE NOTE ARE HEREBY
INCORPORATED HEREIN BY REFERENCE AND SHALL APPLY TO THIS CONSENT LETTER MUTATITIS MUTANDIS AS IF FULLY SET FORTH HEREIN. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company has agreed to reimburse the Holder and the Agent upon the execution of this Consent Letter for its reasonable
and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal costs, fees and expenses actually incurred by the Agent or the Holder in connection with this Consent Letter and the Subject
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,&nbsp;each of the undersigned have caused their respective signature page to this
Consent Letter to be duly executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NOMIS BAY LTD</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ James Keyes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: James Keyes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BPY LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ James Keyes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: James Keyes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ACQUIOM AGENCY SERVICES LLC, as Agent</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Beth Cesari</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Beth Cesari</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Executive Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCLX STOCK ACQUISITION JV LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Xiao Xu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Xiao Xu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Sole Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCILEX HOLDING COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Stephen Ma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Stephen Ma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Tranche B Consent Letter] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>d905678dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;9, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SCLX Stock Acquisition JV </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Rd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Xiao Xu </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Rd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Stephen Ma </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EMAIL </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RE: Consent under Securities Purchase
Agreement and Tranche B Senior Secured Convertible Note (this &#147;<U>Consent Letter</U>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to (i)&nbsp;that certain Securities Purchase Agreement, dated as of October&nbsp;7, 2024 (the &#147;<U>SPA</U>&#148;),
between Scilex Holding Company, a Delaware corporation (the &#147;<U>Company</U>&#148;), each investor listed on the Schedule of Buyers attached thereto, (the &#147;<U>Buyers</U>&#148;) and Acquiom Agency Services LLC, a Colorado limited liability
company (&#147;<U>Acquiom</U>&#148;), as collateral agent, (ii)&nbsp;that certain Tranche B Senior Secured Convertible Note, dated as of October&nbsp;8, 2024 (the &#147;<U>Note</U>&#148;, and together with the Tranche B Senior Secured Convertible
Notes, dated as of such date and held by each other holder thereof, the &#147;<U>Tranche B Notes</U>&#148;), issued by Scilex to the undersigned, as Holder (&#147;<U>Holder</U>&#148;), (iii) that certain Amended and Restated Security Agreement,
dated as of October&nbsp;8, 2024 (the&nbsp;&#147;<U>Security Agreement</U>&#148;), among the Company, SCLX Stock Acquisition JV (&#147;<U>SCLX JV</U>&#148;) and the other subsidiaries of the Company party thereto and Acquiom, as the collateral agent
(the &#147;<U>Agent</U>&#148;) for the holders of the Note and all Other Notes (as defined in the Note), their endorsees, transferees and assigns (collectively with the Agent, the &#147;<U>Secured Parties</U>&#148;) and as collateral agent for the
holders of certain Tranche A Notes (as defined therein), (iv) that certain Senior Secured Promissory Note, dated as of September&nbsp;21, 2023 (the &#147;<U>Tranche A Note</U>&#148;), issued by Scilex to Oramed Pharmaceuticals Inc., as holder (the
&#147;<U>Tranche A Holder</U>&#148;) and (v)&nbsp;all related Transaction Documents, as defined in the SPA.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used but not
defined herein are used with the respective meanings assigned to them in the SPA, the Note, or the Security Agreement, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, if the Company is not able to satisfy its payment obligations pursuant to Section&nbsp;14 of the Tranche B Notes in cash when
due, an Event of Default will occur under the Tranche B Notes (the &#147;<U>Anticipated Events of Default</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, if
an Event of Default occurs under the Note, the Agent and the Holders will be entitled to exercise certain secured creditor remedies pursuant to the Note and the other Transaction Documents, including, without limitation by recourse against the
assets of SCLX JV as a grantor under the Security Agreement; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the parties desire to establish a cash reserve from the proceeds of the sale
of certain assets of SCLX JV (the &#147;<U>Cash Reserve</U>&#148;) in order to obtain in advance, if needed, a limited waiver of certain Anticipated Events of Default that may occur from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, the parties hereto hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1 <U>Limited Waiver of Certain Anticipated Events of Default</U>. If an Anticipated Event of Default occurs, to the extent SCLX
JV pays the balance of the unpaid portion of the applicable Amortization Amount (as defined in the Notes) to the Holder (solely to the extent the Holder has no obligation to turn over such amounts to any other Person pursuant to the Intercreditor
Agreement at such time) on such applicable Amortization Date from the Cash Reserve, such Anticipated Event of Default for any such failure by the Company to pay such Amortization Amount directly to the Holder on such Amortization Date shall be
automatically waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2 <U>Limited Consent and Agreement to Engage in Subject Transactions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Holder hereby consents, and SCLX JV hereby agrees, to (x)&nbsp;transfer (in one or more series of transfers, in each
case after the sale of any Relevant Scilex Share(s)) up to an aggregate of 60,068,585 shares of common stock, par value $0.0001 per share, of the Company (the &#147;<U>Relevant Scilex Shares</U>&#148; and each a &#147;<U>Relevant Scilex
Share</U>&#148;) to an account of SCLX JV at the brokerage firm Curvature Securities LLC or such other brokerage firm or firms as SCLX JV may select , so long as the fee of any such brokerage firm does not exceed the Specified Fee, no exclusivity is
afforded to such brokerage firm and the prior written consent of the Required Holders has been obtained therefor (each such account, a &#147;<U>Designated Brokerage Account</U>&#148; and each such firm, a &#147;<U>Designated Broker</U>&#148;), only
to the extent that SCLX JV has given irrevocable instruction to the applicable Designated Broker that any and all net cash proceeds from any transactions within such Designated Brokerage Account shall be transferred immediately to the Designated
Proceeds Account (as defined bellow) and (y)&nbsp;to engage in sales of the Relevant Scilex Shares to any one or more purchasers in such amounts, at such times, and at such prices as SCLX JV may determine in its sole discretion; <U>provided</U>,
<U>that</U>, the net cash proceeds of any sale of the Relevant Scilex Shares (which the parties hereto acknowledge and agree shall be an amount per share equal to (i)&nbsp;the gross proceeds from such sale paid by a purchaser in respect of a
Relevant Scilex Share <I>minus</I> (ii)&nbsp;solely the Specified Fee (as defined below) payable in respect of such Relevant Scilex Share (such net amount, the &#147;<U>Net Cash Proceeds</U>&#148;)) shall be immediately transferred to that certain
account of SCLX JV at Bank of America, N.A. ending in 3707 (the &#147;<U>Designated Proceeds Account</U>&#148;) and thereafter subject to application pursuant to <U>Section</U><U></U><U>&nbsp;3</U> below (any such transfers, sales and the payment of
the Specified Fee pursuant to this clause (y), collectively, with clause (x), the&nbsp;&#147;<U>Subject Transactions</U>&#148;). For the avoidance of doubt, the Subject Transactions shall not be subject to the provisions of Section&nbsp;9 or
Section&nbsp;10 of the Note. In connection with such consent and agreement, the Holder hereby: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) agrees, and hereby
directs the Agent to agree, that solely upon the substantially simultaneous consummation of the Subject Transactions including the deposit of the Net Cash Proceeds into the Designated Proceeds Account, that any security interest and lien that Agent
and Holder may have solely in the Relevant Scilex Shares shall be released; provided that the security interest and lien in the Net Cash Proceeds of such Relevant Scilex Shares from the Subject Transactions shall not be released. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) agrees, and the Holder hereby directs the Agent to execute and deliver to the Company or SCLX JV, as applicable, any such
additional documents, instruments or releases as are reasonably requested and necessary to give effect to the Subject Transactions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) acknowledges that SCLX JV has agreed to pay (and may in the future
agree to pay) one or more Designated Brokers a sales commission not to exceed 2.5% of the gross proceeds from the sale of a Relevant Scilex Share (such fee, whether paid directly or netted from the gross proceeds of the sale of the Relevant Scilex
Shares, the &#147;<U>Specified Fee</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) by consenting to SCLX JV engaging in the consummation of the Subject
Transactions, waives any violation of: (A)&nbsp;the covenants set forth in Section&nbsp;17(e) and (f)&nbsp;of the Note, in Section&nbsp;4(dd) of the Security Agreement and in Section&nbsp;4(p) of the SPA, in each case solely as each such provision
applies to the Subject Transactions, (B)&nbsp;without limitation of <U>Section</U><U></U><U>&nbsp;4</U>, any provision in the Transaction Documents that requires the Company or SCLX JV, as applicable, to enter into any document or agreement pledging
to the Secured Parties or granting the Secured Parties (or any of them) control over any Designated Brokerage Account (but not, for the avoidance of doubt, the Designated Proceeds Account) or otherwise taking action to grant or perfect a security
interest in favor of the Secured Parties (or any of them) in any Designated Brokerage Account (but not, for the avoidance of doubt, the Designated Proceeds Account) or the Relevant Scilex Shares, and (C)&nbsp;agrees that, subject to compliance with
the terms of this Consent and Demand Letter, including as to the application of proceeds in accordance with <U>Section</U><U></U><U>&nbsp;3</U> hereof, any sale of the Relevant Scilex Shares shall not constitute a &#147;Subsequent Placement&#148; or
&#147;Asset Sale&#148; under the Note and the other Transaction Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) So long as the Required Holders pursuant to
the SPA and Note (as defined therein), as applicable, have consented to the Subject Transactions as set forth herein, such consent shall be binding on all Buyers and holders of Securities pursuant to Section&nbsp;9(e) of the SPA and on all existing
and future holders of any Note pursuant to Section&nbsp;20 of the Note, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The foregoing limited consent
and limited waivers contained in <U>Sections 1</U> and <U>2</U> (i) are <FONT STYLE="white-space:nowrap">one-time</FONT> consent and waivers, (ii)&nbsp;are expressly limited to the consent and waivers described above in
<U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2</U>, (iii) shall not be deemed or otherwise construed to constitute a consent to any other extension, whether or not similar to the consents and waivers described above in
<U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2,</U> and (iv)&nbsp;shall not operate as a waiver of any right, power or remedy of the Agent or any Holder under the Note, any other Transaction Document or any other document,
instrument or agreement executed in connection therewith, nor constitute a waiver, release or modification of the Company&#146;s or any Subsidiary&#146;s obligations to comply with all terms and conditions of the Note and other Transaction
Documents. The Agent and the Holder have granted the limited consent and limited waivers set forth in <U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2</U> in this particular instance and in light of the facts and circumstances
that presently exist, and the grant of such consent shall not constitute a course of dealing or impair the Agent&#146;s or any Holder&#146;s right to withhold any similar consent or waiver in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3 <U>Proceeds of Subject Transaction</U>. Subject to the terms of the Intercreditor Agreement, SCLX JV, the Company and the
Holder hereby agree that (a)&nbsp;on each date on which scheduled amortization payments are due on the Tranche A Note, to the extent the Company fails to pay the required amortization payment on such date, SCLX JV shall deliver (directly, or via
distribution to the Company for such purpose) on such date (each such payment due date, a &#147;<U>Tranche A Payment Date</U>&#148;) the shortfall of any such required amortization payment to the Tranche A Holder from the Net Cash Proceeds from such
Subject Transactions, and (b)&nbsp;on each Amortization Date, to the extent the Company fails to pay the Amortization </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Amount (as defined in the Note) to the Holder, SCLX JV shall deliver (directly, or via distribution to the Company for such purpose) on such date (each such payment due date, a &#147;<U>Tranche B
Payment Date</U>&#148;), the shortfall of any such required Amortization Amount to the Holder from the Net Cash Proceeds from such Subject Transactions. For the avoidance of doubt, the parties acknowledge and agree that amortization payments under
the Tranche A Notes and Tranche B Notes are to be made in the following sequence and in the event that an amortization payment is not made on a Tranche A Payment Date or a Tranche B Payment Date, as applicable, in the full amount thereof in
accordance with the below, SCLX JV shall not make a subsequently due amortization payment pursuant to this <U>Section</U><U></U><U>&nbsp;3</U> until the Company or SCLX JV has first completed all prior amortization payments that remain unsatisfied:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>first</I>, to the Tranche A Holder, an aggregate amount equal to $13,239,205 in satisfaction of the principal
payment due on December&nbsp;21, 2024 under Section&nbsp;2(e) of the Tranche A Note (the &#147;<U>December Tranche A Payment</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>second</I>, from and after the satisfaction of the December Tranche A Payment, to the holders of Tranche B Notes an
aggregate amount equal to and in satisfaction of the Amortization Redemption Price (as defined in the Tranche B Note) due on January&nbsp;2, 2025 (the &#147;<U>January Tranche B Payment</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>third</I>, from and after the satisfaction of the January Tranche B Payment, to the Tranche A Holder until the remaining
outstanding principal amount and accrued and unpaid interest under the Tranche A Note is paid in full in accordance with Section&nbsp;2(e) of the Tranche A Note (the &#147;<U>Final Tranche A Payment</U>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>fourth</I>, from and after the satisfaction of the Final Tranche A Payment, to the holders of Tranche B Notes an
aggregate amount equal to and in satisfaction of the Amortization Redemption Price due on April&nbsp;1, 2025 and the Amortization Redemption Price due on July&nbsp;1, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Holder shall not be entitled to receive and SCLX JV will not be required to deliver, proceeds of any sale of
Relevant Scilex Shares in excess of the aggregate amount required to repay the remaining outstanding principal amount and accrued and unpaid interest under the Note. The Net Cash Proceeds from the sale of the Relevant Scilex Shares may not be
applied or utilized for any purpose other than servicing the payments of principal and interest due under the Tranche A Note and the Tranche B Notes as expressly set forth in this <U>Section</U><U></U><U>&nbsp;3</U>. The payments under the Note
using proceeds of the Subject Transactions and required under this <U>Section</U><U></U><U>&nbsp;3</U> shall be payable without premium or penalty (but, for the avoidance of doubt, shall include the payment of the Make-Whole Amount included in any
such Amortization Redemption Price, as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary or any grace, cure or similar period that
may be set forth in the Transaction Documents and without limitation of any rights of the Agent pursuant to that certain Deposit Account Control Agreement, dated as of March&nbsp;12, 2024, among SCLX JV, the Agent and Bank of America, N.A., the
parties acknowledge and agree that if the Company fails to make any payment required to be made pursuant to this <U>Section</U><U></U><U>&nbsp;3</U> on a Tranche A Payment Date or a Tranche B Payment Date, as applicable, then, effective
automatically as of 12:01 a.m., eastern on the next calendar day and without the requirement of any further action by SCLX JV, the Company or any of their respective affiliates, the Agent has the full right, power and authority to cause and is, by
virtue of this Consent Letter together with contemporaneously delivered consents of the Tranche A Holder and the other holders of Tranche B Notes, directed to cause such amortization payment to be made (to the fullest extent of the funds available
therefore) from the Cash Reserve in the Designated Proceeds Account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4 <U>Grant of Security Interest. </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In consideration for the consent to the Subject Transaction contained herein, and to further secure the complete timely
payment, performance and discharge in full, as the case may be, of all of the Obligations, SCLX JV hereby unconditionally and irrevocably pledges, grants and hypothecates to the Agent (on behalf and for the benefit of the Secured Parties) a security
interest in and to, a lien upon and a right of <FONT STYLE="white-space:nowrap">set-off</FONT> against all of their respective right, title and interest of whatsoever kind and nature in and to the Proceeds of the Relevant Scilex Shares, in whatever
form, including without limitation Payment Intangibles and Supporting Obligations (collectively, the &#147;<U>SCLX Shares Collateral</U>&#148;). SCLX JV and the Company hereby consent and agree to (and agree to cooperate with) the Agent, at the
direction of the Required Holders, taking any and all further action to perfect a security interest in favor of the Secured Parties, including the filing of <FONT STYLE="white-space:nowrap">UCC-1</FONT> financing statements and/or entering into a
control agreement with respect to the SCLX Shares Collateral. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) SCLX JV and the Company hereby agree that they shall
cause to be granted to the Agent (on behalf of and for the benefit of the Secured Parties) a security interest in the Relevant Scilex Shares and/or the Designated Brokerage Account (as specified by the Required Holders and the Tranche A Holder);
<U>provided</U> <U>that</U>, in each case, such security interest may be limited to the extent necessary to ensure that such security interest or the granting thereof does not violate applicable law or impose upon SCLX JV or the Company additional
burdensome filing requirements that exceed the benefit thereof, in each case, as reasonably determined by SCLX JV and/or the Company upon the advice of outside counsel and following good faith consultation with the Required Holders and the Tranche A
Note Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5 <U>Agent Direction</U>. The Holder hereby authorizes and directs the Agent to execute this Consent Letter and
to enter into any documentation reasonably required by <U>Section</U><U></U><U>&nbsp;4</U> above. The Holders&#146; authorization and direction pursuant to this Consent Letter, read simultaneously with the authorization and direction by each other
Holder pursuant to their respective consent letters, collectively constitutes an authorization and direction from all the Holders to enter into each such consent letter and any documentation reasonably required by Sections 4 thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6 <U>Representations and Warranties</U>. In order to induce the Agent and the Holder to enter into this Consent Letter, the
Company hereby represents and warrants as of the date hereof that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) neither it nor any other Person acting on its
behalf has provided any of the undersigned Holders or their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the
Company or any of its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Company has the full right, power and authority to enter into and execute this
Consent Letter and to perform all its obligations hereunder and under the Note and the Transaction Documents, as modified hereby, and SCLX JV has the full right, power and authority to perform the Subject Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the execution and delivery of this Consent Letter has been duly and validly authorized by all necessary action on the part
of the Company, and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with the terms hereof, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other Laws of general application affecting enforcement of creditors&#146; rights generally; and (ii)&nbsp;as limited by Laws relating to the availability of specific performance, injunctive relief or other
equitable remedies; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) neither the execution and delivery of this Consent Letter, nor the
taking of any actions contemplated hereby and the performance of the obligations hereunder or the Subject Transactions by the Company, SCLX JV or any other Subsidiary, does or will, with or without the giving of notice, lapse of time or both,
(i)&nbsp;violate or constitute a default, event of default, or event creating a right of acceleration, termination or cancellation of any obligation under any term or provision of any agreement, credit facility, debt or other instrument evidencing
Company or Subsidiary Indebtedness (after giving effect to any prior or concurrent consents or waivers under any such agreement, credit facility, debt or other instrument to which the Company or such Subsidiary is a party or otherwise subject,
copies of which consents or waivers have been furnished by the Company to the Agent prior to the execution of this Consent Letter); or (ii)&nbsp;violate any rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) no authorization, consent, approval, license, exemption of or filing or registration with any governmental authority, is or
will be necessary for the execution, delivery and performance by the Company of its obligations under this Consent Letter or the performance by SCLX JV of the Subject Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) immediately prior to and after giving effect to this Consent Letter, no Event of Default exists and is continuing on the
date hereof and no Event of Default could reasonably be expected to occur as a result of the Subject Transactions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the
Company has furnished to the Holder a statement setting forth its (i)&nbsp;authorized share capitalization and (ii)&nbsp;issued and outstanding share capitalization, in each case as of the date hereof, and the sale of all or a portion of the
Relevant Scilex Shares shall not constitute an increase to the Company&#146;s outstanding share capital; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;(i)
other than the Specified Fee (if and to the extent it becomes payable in connection with the sale of Relevant Scilex Shares), no broker, finder, agent or investment banker is entitled to any brokerage, finder&#146;s or other fee or commission in
connection with the Subject Transactions from the Company, SCLX JV or any other Subsidiary (any such fees or commissions, &#147;<U>Broker Fees</U>&#148;), and (ii)&nbsp;other than any Designated Broker, no broker, finder, agent or investment banker
has been engaged by the Company, its Subsidiaries or any person acting on their behalf in connection with the Subject Transactions and the Company has furnished to the Agent copies of all agreements or arrangements with any Designated Broker, as of
the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7 <U>Affirmation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as expressly consented pursuant to <U>Section</U><U></U><U>&nbsp;1</U> hereof, the Company hereby expressly
reaffirms, as of the date hereof, all its covenants and agreements contained in the Note and each Transaction Document and agrees that none of its covenants and agreements set forth in the Note or any other Transaction Document shall be reduced or
limited by the execution and delivery of this Consent Letter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company (on behalf of itself and its Subsidiaries)
hereby (i)&nbsp;affirms that each of the Liens granted in or pursuant to the Security Documents are valid and subsisting, and (ii)&nbsp;agrees that this Consent Letter and all documents executed in connection herewith shall in no manner impair or
otherwise adversely affect any of the Liens granted in or pursuant to the Security Documents and such Liens continue unimpaired with the same priority to secure repayment of all Obligations in accordance with the Transaction Documents, whether
heretofore or hereafter incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company (on behalf of itself and its Subsidiaries) hereby
(i)&nbsp;acknowledges and agrees that the Holder has no liability or obligation to pay the Specified Fees or any other Broker Fees and (ii)&nbsp;indemnifies the Holder against and holds it harmless from any and all liabilities (including, without
limitation, reasonable attorneys&#146; fees and disbursements paid or incurred in connection with any such liabilities) for the Specified Fees and any other Broker Fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8 <U>Expiration</U>. If all of the Relevant Scilex Shares have not been sold prior to July&nbsp;1, 2025 (the &#147;<U>Expiration
Date</U>&#148;), then on the Expiration Date, the consents set forth in <U>Section</U><U></U><U>&nbsp;2</U> shall expire and be of no further force and effect with respect to such remaining unsold Relevant Scilex Shares, and the Company, its
Subsidiaries (including SCLX JV) and such remaining unsold Relevant Scilex Shares shall again be subject to all restrictions and limitations pursuant to the Transaction Documents and the organizational documents of the Company and its Subsidiaries
(including SCLX JV) to which the Relevant Scilex Shares (or any proposed transfer thereof) were subject prior to giving effect to the consents set forth herein (other than with respect to any transfers or related transactions required to comply with
the terms of this <U>Section</U><U></U><U>&nbsp;8</U> on and following the Expiration Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9 <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Section headings in this Consent Letter are included herein for convenience of reference only and shall not constitute a
part of this Consent Letter for any other purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This Consent Letter may be executed with counterpart signature
pages or in any number of counterparts, each of which shall be deemed to be an original, but all such separate counterparts shall together constitute but one and the same agreement. In proving this Consent Letter or any other Transaction Document in
any judicial proceedings, it shall not be necessary to produce or account for more than one such counterpart signed by the party against whom such enforcement is sought. Any signatures hereto delivered by electronic transmission shall be deemed an
original signature hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No waiver or modification hereof or of any agreement referred to herein shall be binding or
enforceable unless in writing and signed by all of the parties hereto or thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) From and after the date on which
this Consent Letter shall be effective, the term &#147;Transaction Documents&#148; in the Note and the other Note Documents shall include, without limitation, this Consent Letter and any agreements, instruments and other documents executed and/or
delivered in connection herewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) THE TERMS AND PROVISIONS OF SECTION&nbsp;31 (GOVERNING LAW) OF THE NOTE ARE HEREBY
INCORPORATED HEREIN BY REFERENCE AND SHALL APPLY TO THIS CONSENT LETTER MUTATITIS MUTANDIS AS IF FULLY SET FORTH HEREIN. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company has agreed to reimburse the Holder and the Agent upon the execution of this Consent Letter for its reasonable
and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal costs, fees and expenses actually incurred by the Agent or the Holder in connection with this Consent Letter and the Subject
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,&nbsp;each of the undersigned have caused their respective signature page to this
Consent Letter to be duly executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HOLDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ORAMED PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Nadav Kidron</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Nadav Kidron</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Avi Gabay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Avi Gabay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ACQUIOM AGENCY SERVICES LLC, as Agent</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Beth Cesari</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Beth Cesari</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Executive Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCLX STOCK ACQUISITION JV LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Xiao Xu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Xiao Xu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Sole Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCILEX HOLDING COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Stephen Ma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Stephen Ma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Tranche B Consent Letter] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>d905678dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;9, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SCLX Stock Acquisition JV </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Rd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Xiao Xu </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Rd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Stephen Ma </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EMAIL </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RE: Consent under Securities Purchase
Agreement and Tranche B Senior Secured Convertible Note (this &#147;<U>Consent Letter</U>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to (i)&nbsp;that certain Securities Purchase Agreement, dated as of October&nbsp;7, 2024 (the &#147;<U>SPA</U>&#148;),
between Scilex Holding Company, a Delaware corporation (the &#147;<U>Company</U>&#148;), each investor listed on the Schedule of Buyers attached thereto, (the &#147;<U>Buyers</U>&#148;) and Acquiom Agency Services LLC, a Colorado limited liability
company (&#147;<U>Acquiom</U>&#148;), as collateral agent, (ii)&nbsp;that certain Tranche B Senior Secured Convertible Note, dated as of October&nbsp;8, 2024 (the &#147;<U>Note</U>&#148;, and together with the Tranche B Senior Secured Convertible
Notes, dated as of such date and held by each other holder thereof, the &#147;<U>Tranche B Notes</U>&#148;), issued by Scilex to the undersigned, as Holder (&#147;<U>Holder</U>&#148;), (iii) that certain Amended and Restated Security Agreement,
dated as of October&nbsp;8, 2024 (the&nbsp;&#147;<U>Security Agreement</U>&#148;), among the Company, SCLX Stock Acquisition JV (&#147;<U>SCLX JV</U>&#148;) and the other subsidiaries of the Company party thereto and Acquiom, as the collateral agent
(the &#147;<U>Agent</U>&#148;) for the holders of the Note and all Other Notes (as defined in the Note), their endorsees, transferees and assigns (collectively with the Agent, the &#147;<U>Secured Parties</U>&#148;) and as collateral agent for the
holders of certain Tranche A Notes (as defined therein), (iv) that certain Senior Secured Promissory Note, dated as of September&nbsp;21, 2023 (the &#147;<U>Tranche A Note</U>&#148;), issued by Scilex to Oramed Pharmaceuticals Inc., as holder (the
&#147;<U>Tranche A Holder</U>&#148;) and (v)&nbsp;all related Transaction Documents, as defined in the SPA.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used but not
defined herein are used with the respective meanings assigned to them in the SPA, the Note, or the Security Agreement, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, if the Company is not able to satisfy its payment obligations pursuant to Section&nbsp;14 of the Tranche B Notes in cash when
due, an Event of Default will occur under the Tranche B Notes (the &#147;<U>Anticipated Events of Default</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, if
an Event of Default occurs under the Note, the Agent and the Holders will be entitled to exercise certain secured creditor remedies pursuant to the Note and the other Transaction Documents, including, without limitation by recourse against the
assets of SCLX JV as a grantor under the Security Agreement; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the parties desire to establish a cash reserve from the proceeds of the sale
of certain assets of SCLX JV (the &#147;<U>Cash Reserve</U>&#148;) in order to obtain in advance, if needed, a limited waiver of certain Anticipated Events of Default that may occur from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, the parties hereto hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1 <U>Limited Waiver of Certain Anticipated Events of Default</U>. If an Anticipated Event of Default occurs, to the extent SCLX
JV pays the balance of the unpaid portion of the applicable Amortization Amount (as defined in the Notes) to the Holder (solely to the extent the Holder has no obligation to turn over such amounts to any other Person pursuant to the Intercreditor
Agreement at such time) on such applicable Amortization Date from the Cash Reserve, such Anticipated Event of Default for any such failure by the Company to pay such Amortization Amount directly to the Holder on such Amortization Date shall be
automatically waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2 <U>Limited Consent and Agreement to Engage in Subject Transactions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Holder hereby consents, and SCLX JV hereby agrees, to (x)&nbsp;transfer (in one or more series of transfers, in each
case after the sale of any Relevant Scilex Share(s)) up to an aggregate of 60,068,585 shares of common stock, par value $0.0001 per share, of the Company (the &#147;<U>Relevant Scilex Shares</U>&#148; and each a &#147;<U>Relevant Scilex
Share</U>&#148;) to an account of SCLX JV at the brokerage firm Curvature Securities LLC or such other brokerage firm or firms as SCLX JV may select , so long as the fee of any such brokerage firm does not exceed the Specified Fee, no exclusivity is
afforded to such brokerage firm and the prior written consent of the Required Holders has been obtained therefor (each such account, a &#147;<U>Designated Brokerage Account</U>&#148; and each such firm, a &#147;<U>Designated Broker</U>&#148;), only
to the extent that SCLX JV has given irrevocable instruction to the applicable Designated Broker that any and all net cash proceeds from any transactions within such Designated Brokerage Account shall be transferred immediately to the Designated
Proceeds Account (as defined bellow) and (y)&nbsp;to engage in sales of the Relevant Scilex Shares to any one or more purchasers in such amounts, at such times, and at such prices as SCLX JV may determine in its sole discretion; <U>provided</U>,
<U>that</U>, the net cash proceeds of any sale of the Relevant Scilex Shares (which the parties hereto acknowledge and agree shall be an amount per share equal to (i)&nbsp;the gross proceeds from such sale paid by a purchaser in respect of a
Relevant Scilex Share <I>minus</I> (ii)&nbsp;solely the Specified Fee (as defined below) payable in respect of such Relevant Scilex Share (such net amount, the &#147;<U>Net Cash Proceeds</U>&#148;)) shall be immediately transferred to that certain
account of SCLX JV at Bank of America, N.A. ending in 3707 (the &#147;<U>Designated Proceeds Account</U>&#148;) and thereafter subject to application pursuant to <U>Section</U><U></U><U>&nbsp;3</U> below (any such transfers, sales and the payment of
the Specified Fee pursuant to this clause (y), collectively, with clause (x), the&nbsp;&#147;<U>Subject Transactions</U>&#148;). For the avoidance of doubt, the Subject Transactions shall not be subject to the provisions of Section&nbsp;9 or
Section&nbsp;10 of the Note. In connection with such consent and agreement, the Holder hereby: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) agrees, and hereby
directs the Agent to agree, that solely upon the substantially simultaneous consummation of the Subject Transactions including the deposit of the Net Cash Proceeds into the Designated Proceeds Account, that any security interest and lien that Agent
and Holder may have solely in the Relevant Scilex Shares shall be released; provided that the security interest and lien in the Net Cash Proceeds of such Relevant Scilex Shares from the Subject Transactions shall not be released. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) agrees, and the Holder hereby directs the Agent to execute and deliver to the Company or SCLX JV, as applicable, any such
additional documents, instruments or releases as are reasonably requested and necessary to give effect to the Subject Transactions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) acknowledges that SCLX JV has agreed to pay (and may in the future
agree to pay) one or more Designated Brokers a sales commission not to exceed 2.5% of the gross proceeds from the sale of a Relevant Scilex Share (such fee, whether paid directly or netted from the gross proceeds of the sale of the Relevant Scilex
Shares, the &#147;<U>Specified Fee</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) by consenting to SCLX JV engaging in the consummation of the Subject
Transactions, waives any violation of: (A)&nbsp;the covenants set forth in Section&nbsp;17(e) and (f)&nbsp;of the Note, in Section&nbsp;4(dd) of the Security Agreement and in Section&nbsp;4(p) of the SPA, in each case solely as each such provision
applies to the Subject Transactions, (B)&nbsp;without limitation of <U>Section</U><U></U><U>&nbsp;4</U>, any provision in the Transaction Documents that requires the Company or SCLX JV, as applicable, to enter into any document or agreement pledging
to the Secured Parties or granting the Secured Parties (or any of them) control over any Designated Brokerage Account (but not, for the avoidance of doubt, the Designated Proceeds Account) or otherwise taking action to grant or perfect a security
interest in favor of the Secured Parties (or any of them) in any Designated Brokerage Account (but not, for the avoidance of doubt, the Designated Proceeds Account) or the Relevant Scilex Shares, and (C)&nbsp;agrees that, subject to compliance with
the terms of this Consent and Demand Letter, including as to the application of proceeds in accordance with <U>Section</U><U></U><U>&nbsp;3</U> hereof, any sale of the Relevant Scilex Shares shall not constitute a &#147;Subsequent Placement&#148; or
&#147;Asset Sale&#148; under the Note and the other Transaction Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) So long as the Required Holders pursuant to
the SPA and Note (as defined therein), as applicable, have consented to the Subject Transactions as set forth herein, such consent shall be binding on all Buyers and holders of Securities pursuant to Section&nbsp;9(e) of the SPA and on all existing
and future holders of any Note pursuant to Section&nbsp;20 of the Note, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The foregoing limited consent
and limited waivers contained in <U>Sections 1</U> and <U>2</U> (i) are <FONT STYLE="white-space:nowrap">one-time</FONT> consent and waivers, (ii)&nbsp;are expressly limited to the consent and waivers described above in
<U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2</U>, (iii) shall not be deemed or otherwise construed to constitute a consent to any other extension, whether or not similar to the consents and waivers described above in
<U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2,</U> and (iv)&nbsp;shall not operate as a waiver of any right, power or remedy of the Agent or any Holder under the Note, any other Transaction Document or any other document,
instrument or agreement executed in connection therewith, nor constitute a waiver, release or modification of the Company&#146;s or any Subsidiary&#146;s obligations to comply with all terms and conditions of the Note and other Transaction
Documents. The Agent and the Holder have granted the limited consent and limited waivers set forth in <U>Section</U><U></U><U>&nbsp;1</U> and <U>Section</U><U></U><U>&nbsp;2</U> in this particular instance and in light of the facts and circumstances
that presently exist, and the grant of such consent shall not constitute a course of dealing or impair the Agent&#146;s or any Holder&#146;s right to withhold any similar consent or waiver in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3 <U>Proceeds of Subject Transaction</U>. Subject to the terms of the Intercreditor Agreement, SCLX JV, the Company and the
Holder hereby agree that (a)&nbsp;on each date on which scheduled amortization payments are due on the Tranche A Note, to the extent the Company fails to pay the required amortization payment on such date, SCLX JV shall deliver (directly, or via
distribution to the Company for such purpose) on such date (each such payment due date, a &#147;<U>Tranche A Payment Date</U>&#148;) the shortfall of any such required amortization payment to the Tranche A Holder from the Net Cash Proceeds from such
Subject Transactions, and (b)&nbsp;on each Amortization Date, to the extent the Company fails to pay the Amortization </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Amount (as defined in the Note) to the Holder, SCLX JV shall deliver (directly, or via distribution to the Company for such purpose) on such date (each such payment due date, a &#147;<U>Tranche B
Payment Date</U>&#148;), the shortfall of any such required Amortization Amount to the Holder from the Net Cash Proceeds from such Subject Transactions. For the avoidance of doubt, the parties acknowledge and agree that amortization payments under
the Tranche A Notes and Tranche B Notes are to be made in the following sequence and in the event that an amortization payment is not made on a Tranche A Payment Date or a Tranche B Payment Date, as applicable, in the full amount thereof in
accordance with the below, SCLX JV shall not make a subsequently due amortization payment pursuant to this <U>Section</U><U></U><U>&nbsp;3</U> until the Company or SCLX JV has first completed all prior amortization payments that remain unsatisfied:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>first</I>, to the Tranche A Holder, an aggregate amount equal to $13,239,205 in satisfaction of the principal
payment due on December&nbsp;21, 2024 under Section&nbsp;2(e) of the Tranche A Note (the &#147;<U>December Tranche A Payment</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>second</I>, from and after the satisfaction of the December Tranche A Payment, to the holders of Tranche B Notes an
aggregate amount equal to and in satisfaction of the Amortization Redemption Price (as defined in the Tranche B Note) due on January&nbsp;2, 2025 (the &#147;<U>January Tranche B Payment</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>third</I>, from and after the satisfaction of the January Tranche B Payment, to the Tranche A Holder until the remaining
outstanding principal amount and accrued and unpaid interest under the Tranche A Note is paid in full in accordance with Section&nbsp;2(e) of the Tranche A Note (the &#147;<U>Final Tranche A Payment</U>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>fourth</I>, from and after the satisfaction of the Final Tranche A Payment, to the holders of Tranche B Notes an
aggregate amount equal to and in satisfaction of the Amortization Redemption Price due on April&nbsp;1, 2025 and the Amortization Redemption Price due on July&nbsp;1, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Holder shall not be entitled to receive and SCLX JV will not be required to deliver, proceeds of any sale of
Relevant Scilex Shares in excess of the aggregate amount required to repay the remaining outstanding principal amount and accrued and unpaid interest under the Note. The Net Cash Proceeds from the sale of the Relevant Scilex Shares may not be
applied or utilized for any purpose other than servicing the payments of principal and interest due under the Tranche A Note and the Tranche B Notes as expressly set forth in this <U>Section</U><U></U><U>&nbsp;3</U>. The payments under the Note
using proceeds of the Subject Transactions and required under this <U>Section</U><U></U><U>&nbsp;3</U> shall be payable without premium or penalty (but, for the avoidance of doubt, shall include the payment of the Make-Whole Amount included in any
such Amortization Redemption Price, as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary or any grace, cure or similar period that
may be set forth in the Transaction Documents and without limitation of any rights of the Agent pursuant to that certain Deposit Account Control Agreement, dated as of March&nbsp;12, 2024, among SCLX JV, the Agent and Bank of America, N.A., the
parties acknowledge and agree that if the Company fails to make any payment required to be made pursuant to this <U>Section</U><U></U><U>&nbsp;3</U> on a Tranche A Payment Date or a Tranche B Payment Date, as applicable, then, effective
automatically as of 12:01 a.m., eastern on the next calendar day and without the requirement of any further action by SCLX JV, the Company or any of their respective affiliates, the Agent has the full right, power and authority to cause and is, by
virtue of this Consent Letter together with contemporaneously delivered consents of the Tranche A Holder and the other holders of Tranche B Notes, directed to cause such amortization payment to be made (to the fullest extent of the funds available
therefore) from the Cash Reserve in the Designated Proceeds Account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4 <U>Grant of Security Interest. </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In consideration for the consent to the Subject Transaction contained herein, and to further secure the complete timely
payment, performance and discharge in full, as the case may be, of all of the Obligations, SCLX JV hereby unconditionally and irrevocably pledges, grants and hypothecates to the Agent (on behalf and for the benefit of the Secured Parties) a security
interest in and to, a lien upon and a right of <FONT STYLE="white-space:nowrap">set-off</FONT> against all of their respective right, title and interest of whatsoever kind and nature in and to the Proceeds of the Relevant Scilex Shares, in whatever
form, including without limitation Payment Intangibles and Supporting Obligations (collectively, the &#147;<U>SCLX Shares Collateral</U>&#148;). SCLX JV and the Company hereby consent and agree to (and agree to cooperate with) the Agent, at the
direction of the Required Holders, taking any and all further action to perfect a security interest in favor of the Secured Parties, including the filing of <FONT STYLE="white-space:nowrap">UCC-1</FONT> financing statements and/or entering into a
control agreement with respect to the SCLX Shares Collateral. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) SCLX JV and the Company hereby agree that they shall
cause to be granted to the Agent (on behalf of and for the benefit of the Secured Parties) a security interest in the Relevant Scilex Shares and/or the Designated Brokerage Account (as specified by the Required Holders and the Tranche A Holder);
<U>provided</U> <U>that</U>, in each case, such security interest may be limited to the extent necessary to ensure that such security interest or the granting thereof does not violate applicable law or impose upon SCLX JV or the Company additional
burdensome filing requirements that exceed the benefit thereof, in each case, as reasonably determined by SCLX JV and/or the Company upon the advice of outside counsel and following good faith consultation with the Required Holders and the Tranche A
Note Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5 <U>Agent Direction</U>. The Holder hereby authorizes and directs the Agent to execute this Consent Letter and
to enter into any documentation reasonably required by <U>Section</U><U></U><U>&nbsp;4</U> above. The Holders&#146; authorization and direction pursuant to this Consent Letter, read simultaneously with the authorization and direction by each other
Holder pursuant to their respective consent letters, collectively constitutes an authorization and direction from all the Holders to enter into each such consent letter and any documentation reasonably required by Sections 4 thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6 <U>Representations and Warranties</U>. In order to induce the Agent and the Holder to enter into this Consent Letter, the
Company hereby represents and warrants as of the date hereof that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) neither it nor any other Person acting on its
behalf has provided any of the undersigned Holders or their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the
Company or any of its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Company has the full right, power and authority to enter into and execute this
Consent Letter and to perform all its obligations hereunder and under the Note and the Transaction Documents, as modified hereby, and SCLX JV has the full right, power and authority to perform the Subject Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the execution and delivery of this Consent Letter has been duly and validly authorized by all necessary action on the part
of the Company, and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with the terms hereof, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other Laws of general application affecting enforcement of creditors&#146; rights generally; and (ii)&nbsp;as limited by Laws relating to the availability of specific performance, injunctive relief or other
equitable remedies; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) neither the execution and delivery of this Consent Letter, nor the
taking of any actions contemplated hereby and the performance of the obligations hereunder or the Subject Transactions by the Company, SCLX JV or any other Subsidiary, does or will, with or without the giving of notice, lapse of time or both,
(i)&nbsp;violate or constitute a default, event of default, or event creating a right of acceleration, termination or cancellation of any obligation under any term or provision of any agreement, credit facility, debt or other instrument evidencing
Company or Subsidiary Indebtedness (after giving effect to any prior or concurrent consents or waivers under any such agreement, credit facility, debt or other instrument to which the Company or such Subsidiary is a party or otherwise subject,
copies of which consents or waivers have been furnished by the Company to the Agent prior to the execution of this Consent Letter); or (ii)&nbsp;violate any rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) no authorization, consent, approval, license, exemption of or filing or registration with any governmental authority, is or
will be necessary for the execution, delivery and performance by the Company of its obligations under this Consent Letter or the performance by SCLX JV of the Subject Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) immediately prior to and after giving effect to this Consent Letter, no Event of Default exists and is continuing on the
date hereof and no Event of Default could reasonably be expected to occur as a result of the Subject Transactions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the
Company has furnished to the Holder a statement setting forth its (i)&nbsp;authorized share capitalization and (ii)&nbsp;issued and outstanding share capitalization, in each case as of the date hereof, and the sale of all or a portion of the
Relevant Scilex Shares shall not constitute an increase to the Company&#146;s outstanding share capital; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;(i)
other than the Specified Fee (if and to the extent it becomes payable in connection with the sale of Relevant Scilex Shares), no broker, finder, agent or investment banker is entitled to any brokerage, finder&#146;s or other fee or commission in
connection with the Subject Transactions from the Company, SCLX JV or any other Subsidiary (any such fees or commissions, &#147;<U>Broker Fees</U>&#148;), and (ii)&nbsp;other than any Designated Broker, no broker, finder, agent or investment banker
has been engaged by the Company, its Subsidiaries or any person acting on their behalf in connection with the Subject Transactions and the Company has furnished to the Agent copies of all agreements or arrangements with any Designated Broker, as of
the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7 <U>Affirmation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as expressly consented pursuant to <U>Section</U><U></U><U>&nbsp;1</U> hereof, the Company hereby expressly
reaffirms, as of the date hereof, all its covenants and agreements contained in the Note and each Transaction Document and agrees that none of its covenants and agreements set forth in the Note or any other Transaction Document shall be reduced or
limited by the execution and delivery of this Consent Letter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company (on behalf of itself and its Subsidiaries)
hereby (i)&nbsp;affirms that each of the Liens granted in or pursuant to the Security Documents are valid and subsisting, and (ii)&nbsp;agrees that this Consent Letter and all documents executed in connection herewith shall in no manner impair or
otherwise adversely affect any of the Liens granted in or pursuant to the Security Documents and such Liens continue unimpaired with the same priority to secure repayment of all Obligations in accordance with the Transaction Documents, whether
heretofore or hereafter incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company (on behalf of itself and its Subsidiaries) hereby
(i)&nbsp;acknowledges and agrees that the Holder has no liability or obligation to pay the Specified Fees or any other Broker Fees and (ii)&nbsp;indemnifies the Holder against and holds it harmless from any and all liabilities (including, without
limitation, reasonable attorneys&#146; fees and disbursements paid or incurred in connection with any such liabilities) for the Specified Fees and any other Broker Fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8 <U>Expiration</U>. If all of the Relevant Scilex Shares have not been sold prior to July&nbsp;1, 2025 (the &#147;<U>Expiration
Date</U>&#148;), then on the Expiration Date, the consents set forth in <U>Section</U><U></U><U>&nbsp;2</U> shall expire and be of no further force and effect with respect to such remaining unsold Relevant Scilex Shares, and the Company, its
Subsidiaries (including SCLX JV) and such remaining unsold Relevant Scilex Shares shall again be subject to all restrictions and limitations pursuant to the Transaction Documents and the organizational documents of the Company and its Subsidiaries
(including SCLX JV) to which the Relevant Scilex Shares (or any proposed transfer thereof) were subject prior to giving effect to the consents set forth herein (other than with respect to any transfers or related transactions required to comply with
the terms of this <U>Section</U><U></U><U>&nbsp;8</U> on and following the Expiration Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9 <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Section headings in this Consent Letter are included herein for convenience of reference only and shall not constitute a
part of this Consent Letter for any other purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This Consent Letter may be executed with counterpart signature
pages or in any number of counterparts, each of which shall be deemed to be an original, but all such separate counterparts shall together constitute but one and the same agreement. In proving this Consent Letter or any other Transaction Document in
any judicial proceedings, it shall not be necessary to produce or account for more than one such counterpart signed by the party against whom such enforcement is sought. Any signatures hereto delivered by electronic transmission shall be deemed an
original signature hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No waiver or modification hereof or of any agreement referred to herein shall be binding or
enforceable unless in writing and signed by all of the parties hereto or thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) From and after the date on which
this Consent Letter shall be effective, the term &#147;Transaction Documents&#148; in the Note and the other Note Documents shall include, without limitation, this Consent Letter and any agreements, instruments and other documents executed and/or
delivered in connection herewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) THE TERMS AND PROVISIONS OF SECTION&nbsp;31 (GOVERNING LAW) OF THE NOTE ARE HEREBY
INCORPORATED HEREIN BY REFERENCE AND SHALL APPLY TO THIS CONSENT LETTER MUTATITIS MUTANDIS AS IF FULLY SET FORTH HEREIN. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company has agreed to reimburse the Holder and the Agent upon the execution of this Consent Letter for its reasonable
and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal costs, fees and expenses actually incurred by the Agent or the Holder in connection with this Consent Letter and the Subject
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,&nbsp;each of the undersigned have caused their respective signature page to this
Consent Letter to be duly executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>3i LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Maier J. Tarlow</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Maier J. Tarlow</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: Manager On Behalf Of 3i Management LLC,<BR>The GP of 3i LP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ACQUIOM AGENCY SERVICES LLC, as Agent</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Beth Cesari</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Beth Cesari</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Executive Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCLX STOCK ACQUISITION JV LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Xiao Xu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Xiao Xu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Sole Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCILEX HOLDING COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Stephen Ma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Stephen Ma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Tranche B Consent Letter] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>sclxw-20241209.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 12/10/2024 12:55:08 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:sclxw="http://imetrix.edgar-online.com/20241209"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://imetrix.edgar-online.com/20241209"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" namespace="http://fasb.org/us-types/2024" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sclxw-20241209_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sclxw-20241209_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sclxw-20241209_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sclxw_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="sclxw_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sclxw-20241209_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 12/10/2024 12:55:11 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sclxw-20241209.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="sclxw-20241209.xsd#sclxw_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="sclxw-20241209.xsd#sclxw_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="sclxw_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclxw_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="53.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sclxw-20241209_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 12/10/2024 12:55:08 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="sclxw-20241209.xsd#sclxw_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclxw_DocumentAndEntityInformationTable" xlink:to="sclxw_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="sclxw_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="sclxw_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="sclxw-20241209.xsd#sclxw_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="sclxw_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="sclxw_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="sclxw_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sclxw-20241209_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 12/10/2024 12:55:09 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sclxw-20241209.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="sclxw-20241209.xsd#sclxw_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="sclxw_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="sclxw-20241209.xsd#sclxw_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationTable" xlink:to="sclxw_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="53.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46394585955488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclxw_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Scilex Holding Co<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001820190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  09,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">92-1062542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">960 San Antonio Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">516-4310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclxw_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SCLX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclxw_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SCLXW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclxw_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclxw_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclxw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
M]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NX
MZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#
MS"=X87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;
M9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'
MGL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G
M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" "Z,(I9EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "Z,(I9!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( +HPBEGH=,C\[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +HPBEF97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MNC"*6:U0\OH%!0  $18  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +HPBEF?H!OPL0(  .(,   -
M          "  4@-  !X;"]S='EL97,N>&UL4$L! A0#%     @ NC"*69>*
MNQS     $P(   L              ( !)!   %]R96QS+RYR96QS4$L! A0#
M%     @ NC"*61PX9>H_ 0  / (   \              ( !#1$  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( +HPBEDD'INBK0   /@!   :
M      "  7D2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( +HPBEEED'F2&0$  ,\#   3              "  5X3  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  *@4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d905678d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d905678d8k.htm">d905678d8k.htm</File>
    <File>sclxw-20241209.xsd</File>
    <File>sclxw-20241209_def.xml</File>
    <File>sclxw-20241209_lab.xml</File>
    <File>sclxw-20241209_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d905678d8k.htm": {
   "nsprefix": "sclxw",
   "nsuri": "http://imetrix.edgar-online.com/20241209",
   "dts": {
    "inline": {
     "local": [
      "d905678d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "sclxw-20241209.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "sclxw-20241209_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sclxw-20241209_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sclxw-20241209_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 26
   },
   "report": {
    "R1": {
     "role": "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-12-09_to_2024-12-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d905678d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-12-09_to_2024-12-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d905678d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sclxw_DocumentAndEntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://imetrix.edgar-online.com/20241209",
     "localname": "DocumentAndEntityInformationLineItems",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sclxw_DocumentAndEntityInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://imetrix.edgar-online.com/20241209",
     "localname": "DocumentAndEntityInformationTable",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://imetrix.edgar-online.com//20241209/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-24-273896-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-273896-xbrl.zip
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M?P9NXBK7[IO<9E/RJVNC0B%=][R\0-0*D?/Q.Q/F6/!_\-&FH\<.+"?+I_>
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M[E&;L"DSPX#?8^@!PLE$ ;6C'<K"@;^Y!XRPV)HTR<&$<A[5_?3#:=5X>R9
M;]G,&[L.(X[4B$G2P4FBDO8U:0B4E0ZT>^:*&\#;DT;E>+64X,E9U$L7U.T-
M3NVY%K]1S;4;QDFQ7C-6:AW2TZDOL;A7Y<[+R\='T#C@,*@XW)<*""ZIDAK
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M/XMW212$\40<);.Y'U]_:]0MHY9OB;IEY/(-M\G4,LCE?"IC\=Y?M<>O(W5
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M4$5WU\N([724)V8#.\H&K5#:PA(N)F8)D!G>84AMN9$)F+$V1M?]]M$FCG4
M*Y!C\"#@@&247+5H/[A\ O])FXVL&(+4#OT4>0EV8#U9S/T4X,3K))RI12.B
MGD3@Q@A(-DA$%,Y"/)4H](=AA+L=&<9A>ATE400'EP))^DQ7SBE5:0LD1TKW
M30E[!E02K0B9'T6B'01T-+ F?I\YVP>4ZAN0O^'O,!6 XB3-I,P\D:=^G*$
M4H+0SS+PGF -A%2.\O!21M?B*LRGM X!Z(E%U"*5P[G!<3I<2BLN[KIF6YH
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MKV0,;2]C%;M3Z![PV#!/%>A0P;OZ!KUU^A((E:G,"C,!;X+/DBJF8#M7Y4?
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M,J.GPB@)WH# M/D0QO]LW7.K\"MJ]^[=M&].]M'NQR>@NP;AM5A#=)*@>@L
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M_[>PI[Y0MV/=J,ZB_9;+$%2CA"CMLD9H-88ZR](ED'::7;?P\T2N"LMSV'M
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MFQR?B\GH?X$^'F[I=2E,MO^WY_1_6^+]Z&AZ_,O6@]W=?YA(U&!X,AV>_Y!
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M>WN[C[G8"&^H/!AE*P%\$BR(C;L=6P*@DG-F0:B.KD=5G[05=[""&BZ'- I
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M@!OIS@'#ZW4!1S-T*"R5MW[IQU$86XJ;AZ;0*!YM%>H,:*(R&UE!$Q0MBF%
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M1].'Z@+61O^:)"S1GIDJNF["B1YP8NK?43(#F!)I!EP@PBNWUP_1GZ4A>&S
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MEA<+N&Z?1@8JG)FW,54MAAB=P$+2+$VB@.6;#A_6,873$S22JC75DK=/T6!
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MWH Q3H]^AP^/IV_&!_\/4$L#!!0    ( +HPBEE5#>8B\20  'FB   1
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M X$=BIOK":9^6-LQ#QO%)&[%JG5"7.=$\-3O^>$X"28@:K<#XP.*AT9M Q@
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MZ/O&_V<BA1TA#6",TZ,_X,.7LU>3_?\'4$L#!!0    ( +HPBEG@HXH%Z@,
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M_<#J$HTRM*E9:IMO>FZDF'/OWIP2;4OYC(AYPE\ESJK(U<6*G_\#4$L#!!0
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M,"AE9S3QVRP2:=DK#H8WA%,6G,7!J7QG7I?'C>26P31;815!&*@:!+&934N
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M.3 U-C<X9#AK+FAT;5!+ 0(4 Q0    ( +HPBEE$ %8L"B<  #Z_   1
M          "  5 6  !D.3 U-C<X9&5X,3 Q+FAT;5!+ 0(4 Q0    ( +HP
MBEE4W!]TXB0  /ND   1              "  8D]  !D.3 U-C<X9&5X,3 R
M+FAT;5!+ 0(4 Q0    ( +HPBEEHCW.(^B0  "*E   1              "
M 9IB  !D.3 U-C<X9&5X,3 S+FAT;5!+ 0(4 Q0    ( +HPBEE5#>8B\20
M 'FB   1              "  <.'  !D.3 U-C<X9&5X,3 T+FAT;5!+ 0(4
M Q0    ( +HPBEG@HXH%Z@,  '4/   2              "  >.L  !S8VQX
M=RTR,#(T,3(P.2YX<V102P$"% ,4    " "Z,(I9</J]M=@%  #0-0  %@
M            @ ']L   <V-L>'<M,C R-#$R,#E?9&5F+GAM;%!+ 0(4 Q0
M   ( +HPBEG)X25"V@<  *M8   6              "  0FW  !S8VQX=RTR
M,#(T,3(P.5]L86(N>&UL4$L! A0#%     @ NC"*60_@&_F3!0  FSD  !8
M             ( !%[\  '-C;'AW+3(P,C0Q,C Y7W!R92YX;6Q02P4&
/  D "0!$ @  WL0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>d905678d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sclxw-20241209.xsd" xlink:type="simple"/>
    <context id="duration_2024-12-09_to_2024-12-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2024-12-09</startDate>
            <endDate>2024-12-09</endDate>
        </period>
    </context>
    <context id="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-09</startDate>
            <endDate>2024-12-09</endDate>
        </period>
    </context>
    <context id="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-09</startDate>
            <endDate>2024-12-09</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2024-12-09_to_2024-12-09"
      id="Hidden_dei_EntityRegistrantName">Scilex Holding Co</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-315">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-12-09_to_2024-12-09"
      id="Hidden_dei_EntityCentralIndexKey">0001820190</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-342">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-343">2024-12-09</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-344">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-345">001-39852</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-346">92-1062542</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-347">960 San Antonio Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-348">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-349">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-350">94303</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-351">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-352">516-4310</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-353">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-354">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-355">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-356">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-357">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-358">SCLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-359">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember"
      id="ixv-360">Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember"
      id="ixv-361">SCLXW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-12-09_to_2024-12-09_us-gaap-StatementClassOfStockAxis_us-gaap-WarrantMember"
      id="ixv-362">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-363">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2024-12-09_to_2024-12-09" id="ixv-364">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
